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3. ABSTRACT 
The incidence of gastric cancer in the last decades has declined rapidly in the 
industrialised countries. Worldwide, however, gastric cancer is still the second most 
common cause of cancer death. Although surgery is currently the most effective 
treatment, the rapid progress in adjuvant chemotherapy and radiation therapy requires 
a re-evaluation of prognosis assessment. The TNM staging system of the UICC is 
ubiquitously used; it groups patients by decreasing survival times from stage I to stage 
IV based on the spread of disease, i.e., depth of tumour penetration (T), extent of 
spread to regional lymph nodes (N), and the presence or absence of distant (M) 
metastases. This is by far the most consistent prognostic classification system today. 
However, even within the stage groups there are patients that follow a varying course 
of disease. Our knowledge of the molecular differences between tumours of the same 
stage and morphology has been accumulating over the years and methods for a more 
accurate assessment of the phenotype of neoplasias are of value when evaluating the 
prognosis of individual patients with gastric cancer. 
In this study, the immunohistochemical expression of tumour markers involved in 
different phases in tumourigenesis was examined. The aim was to find new markers 
which could provide prognostic information in addition to what is provided by the 
TNM variables. A total of 337 specimens from the primary tumour of patients who 
underwent surgery for gastric cancer were collected and the immunohistochemical 
expression of seven different biomarkers was analysed. DNA ploidy and S-phase 
fraction (SPF) was assessed by flow cytometry. Finally, all biomarkers and 
clinicopathological prognostic factors were combined and evaluated by a multivariate 
Cox regression model to elucidate which specific factors provide independent 
prognostic information.
By univariate survival analysis the following variables were significant prognostic 
factors: epithelial and stromal syndecan-1 expression, stromal tenascin-C expression, 
expression of tumour-associated trypsin inhibitor (TATI) in cancer cells, nuclear p53 
expression, nuclear p21 expression, DNA ploidy, and SPF. By multivariate survival 
analysis adjusted for all available clinicopathological and biomolecular variables, p53 
expression, p21 expression, and DNA ploidy emerged as independent prognostic 
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biomarkers, together with penetration depth of the tumour, presence of regional nodal 
metastases, surgical cure of the cancer, and age of the patient at the time of diagnosis.
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4. INTRODUCTION 
Knowledge of the outcome after surgery of patients with gastric cancer is crucial for 
subsequent planning of treatment and follow-up. Although the incidence of gastric 
cancer has rapidly declined in the industrialised countries after the Second World War, 
gastric cancer is still the fourth most common cause of cancer death in Finland and the 
second most common worldwide, preceded only by lung cancer. The incidence of 
gastric cancer in Finland in 2003 was 9.6/100,000 for men (424 new cases) and 
5.2/100,000 for women (347 new cases), which accounts for 3.4 % of all cancers in 
men and for 2.9 % in women (Finnish Cancer Registry, 2005). Mortality due to gastric 
cancer among men was 7.1/100,000 (314 deaths) and among women 3.3/100,000 (248 
deaths), which makes gastric cancer the 4th and 6th most common killer cancer, 
accounting for 5.8 % and 4.9 % of all cancer deaths, respectively. The predicted 5-year 
relative survival rates of patients diagnosed with gastric cancer in 1999 – 2001 are 27 
% for men and 31 % for women (Finnish Cancer Registry, 2005). Prognosis is worse 
only for cancer of the pancreas, liver, gall bladder, oesophagus, and lung and trachea. 
A difference in the incidence of gastric cancer by socioeconomic status is evident for 
both men and women: the risk is higher in the lowest socioeconomic group than in the 
highest. This may partly be explained by dietary factors and the prevalence of 
Helicobacter pylori infection. The incidence of gastric cancer rises with increasing 
age: in the age group 25 – 29 years it is 0.2/100,000 standardised person years and in 
the age group of 85 and older it is 177.8.
The only potentially curative treatment of gastric cancer today is total surgical removal 
of the primary tumour and the affected lymph nodes. However, a large number of 
clinical trials are currently ongoing in an effort to develop more effective adjuvant 
therapies. Before a patient is decided to be put on adjuvant therapy, it would naturally 
be most important to know the risk of disease recurrence and prognosis. This would 
make it possible to target treatments accurately to patients that would benefit and to 
avoid potentially harmful treatments of patients who would not benefit. In addition to 
improved patient care also considerable economical advantages are involved.
The most commonly used and validated prognostic tool today is the TNM-stage 
classification system, which focuses on the anatomic extent of the disease at the time 
of detection. It is based on a collective evaluation of the depth of tumour penetration 
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(pT), regional lymph node involvement (pN) and presence or absence of distant 
metastases (pM). More accurate prognostic tools are, however, needed. Patients with 
stage I cancer have a favourable prognosis with a 5-year survival of 90 – 95 %. Some 
of the patients will, however, ultimately die of the cancer and they would benefit from 
further treatments. Stage IV patients have an unfavourable prognosis with 5-year 
survival of 0 – 30 %, but, again, a considerable number of patients survive also in this 
subgroup. The survival for stage II-III patients is much more variable and more 
accurate prognostic tools are urgently needed especially for these patients. 
Development of malignant neoplasia is a multistep process, which involves several 
disturbances in the control mechanisms of cellular growth. It is possible to detect 
molecular changes which differ between malignant and healthy cells. 
Immunohistochemistry is a well established method to study the expression of specific 
antigens in tissues and can be used to examine cancer-specific expression patterns. 
Flow cytometric analysis of the DNA ploidy and S-phase fraction is another well 
established method to assess the amount of DNA in a cell suspension and the level of 
chromosomal derangements in a specimen. 
The prognostic value of the different biomarkers has generally been studied one at a 
time. Prognosis-setting could be improved by a model that would use information from 
several independent prognostic factors. In this study exploratory analyses of single 
new biomarkers were performed, and attempts were made to find the most accurate 
combination of prognostic variable markers with regard to patient outcome. The study 
was conducted on patients with gastric adenocarcinoma only, to be distinguished from 
gastric lymphoma and leiomyosarcoma, which have different tumour biology. Of all 
gastric tumours about 90 to 95 % are adenocarcinomas. This study was performed to 
identify new prognostic tumour markers and to combine them into a prognostic model 
in order to improve the prediction of the outcome of patients with gastric cancer.
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5. REVIEW OF THE LITERATURE 
5.1 Types of gastric cancer 
The stomach consists of five different layers: mucosa, submucosa, muscularis, 
subserosa, and serosa. Malignancies may develop in any of these layers. The most 
common of the gastric cancers is the adenocarcinoma, which makes up 90 – 95 % of 
all gastric malignancies. Adenocarcinoma arises from the glandular epithelial cells of 
the inner mucosal layer of the stomach. Other types of gastric malignancies are mainly 
lymphomas and gastrointestinal stromal tumours (GISTs). Lymphomas are rare 
tumours of the lymphatic system, of which the mucosa-associated lymphoid tissue 
(MALT) lymphomas are the most common in the stomach. Rarely, neuroendocrine 
tumours arise in the stomach. Occasionally the stomach is the site for metastasis, 
usually from an adenocarcinoma originated from the pancreas, breast, or ovary.
The stomach is composed of the cardia, which is the mouth of the stomach from 
oesophagus, and caudally leftwards of the fundus. The major part of the stomach 
consists of the body or corpus, with the lesser curvature to the upper right and the 
greater curvature to the lower left. The mucosa of the fundus and corpus is folded 
(rugae); the distal third of the stomach is devoid of such folds. The antrum is marked 
by the incisura angularis proximally and by the pyloric region distally. Roughly 15 % 
of the gastric cancers develop in the upper, 40 % in the middle, and 40 % in the distal 
part of the stomach. About 10 % of the cancers engage more than one of the parts at 
the time of diagnosis. The incidence of gastric cardia cancer has increased in the 
industrialised countries (Botterweck et al., 2000; Kocher et al., 2001; Blaser et al., 
2002).
5.2 Epidemiology 
Gastric adenocarcinoma is an important cause of mortality and morbidity worldwide. It 
is the second most common cause of cancer-related deaths with approximately 700,000 
deaths in 2002 (Boyle, 1997; Torrado et al., 2001; Roder, 2002). The incidence has 
rapidly declined in the industrialised countries over the last 5 decades but it is still high 
in countries like Japan (59.9 men and 23.8 women per 100,000 persons in 1993-97), 
Korea, China, Central and South American, and the East European countries. In 1957 
the number of new gastric cancer cases in Finland was 1,876 but in 2003 only 783 
(Finnish Cancer Registry, 2005) (Figure 1). The incidence of gastric cancer increases 
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with age and is highest in the age group above 50. The median age at diagnosis is 
about 65 years. There were on average 764 new cases of gastric cancer diagnosed 
annually in 1999 – 2004 per year, with 603 (79 %) of the patients being 60 years or 
older (Finnish Cancer Registry, 2005). Gastric cancer is 1.5 – 2.0 times more prevalent 
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Figure 1. Incidence per 100,000 inhabitants of gastric cancer in Finland from 1957 to 2003. 
Men (blue line) and women (red line) (Finnish Cancer Registry, 2005). 
Mortality related to gastric cancer is high. In 2003, gastric cancer was the fourth most 
common cause of cancer-related deaths among Finnish men, preceded only by lung, 
prostate and pancreas cancer. There were 314 deaths (5.8 % of all cancer deaths for 
men, 7.1/100,000 persons) in 2003. In women gastric cancer was the sixth most 
common cause of cancer related deaths, preceded by breast, lung, pancreas, colon, and 
ovarian cancer (4.9 % of all, 3.3/100,000 persons) (Finnish Cancer Registry, 2005). 
The predicted 5-year survival of men diagnosed with gastric cancer from 1999 to 2001 
in Finland is 27 % and of women 31 % (Finnish Cancer Registry, 2005).
There is some evidence that patients with gastric cancer of Asian descent have a better 
prognosis. This may be due to a greater frequency of early stage disease, different 
staging classification, earlier detection of disease due to screening, more distant 
tumour location, and perhaps more extensive surgery as is customary in Asian 
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hospitals (Hundahl et al., 1996; Noguchi et al., 2000). There seem also to be 
differences in disease patterns between patients with different ethnicity within Western 
treatment centres. Japanese Americans have an advantage in stage-stratified gastric 
cancer survival mainly because they have fewer proximal tumours, a lower male-to-
female gastric cancer ratio, and less often undergo adjacent organ resection (Hundahl 
et al., 2000). Patients of Asian descent tend also to be younger, precent with less 
distant metastases, and more likely undergo curative resection (Theuer et al., 2000; 
Schwarz et al., 2002; Gill et al., 2003).
5.3 Aetiology and risk factors 
The mechanism of how gastric cancer develops is unknown. Of all gastric cancers, 
only 1 % is hereditary (Caldas et al., 1999), and when this is the case, the patient is 
usually younger than 40 years (Caldas et al., 1999). Familial hereditary gastric 
polyposis with a high incidence of gastric cancer has been described (Seruca et al., 
1991). Chronic atrophic gastritis followed by intestinal metaplasia is a precancerous 
lesion linked to development of malignant gastric neoplasia. Pernicious anaemia is, in 
turn, linked to chronic atrophic gastritis.
An important aspect of gastric carcinogenesis is the infection of Helicobacter pylori,
which gives rise to a variety of inflammatory responses. This variation is partly due to 
the genetic variation of H. pylori and partly to different immunological responses of 
the patient (Kaminishi, 2005). Several factors as salty food, nitrite and N-nitroso 
compounds, lack of vitamin C, individual immunogenic response, interleukin-1 
polymorphism, and H. pylori infection all interact over a long time span and may 
finally induce gastric cancer. 
5.3.1 Helicobacter pylori infection 
The H. pylori organism was found by Marshall and Warren in 1982 (Marshall & 
Warren, 1984). This bacterium has been closely linked to gastritis and the risk of 
gastric cancer among infected individuals is increased 2- to 9-fold (Eslick et al., 1999; 
Huang et al., 2003). Although all patients with H. pylori infection show signs of 
gastritis, only a small percent of them ultimately develop gastric ulcer and much less 
cancer. Based on epidemiologic findings WHO declared in 1994 that H. pylori is a 
carcinogen and constitutes a risk factor for gastric cancer. H. pylori infection, 
14
especially the CagA-positive strain, is associated particularly with noncardia gastric 
adenocarcinoma, but the risk of gastric cancer among patients with CagA-negative H.
pylori is also significantly increased when compared to uninfected persons (Parsonnet 
et al., 1997; Enroth et al., 2000; Nomura et al., 2002; Huang et al., 2003; Wu et al., 
2003; Held et al., 2004; Machida-Montani et al., 2004; Lopez-Carrillo et al., 2004).
Smoking adds significantly to the raised risk of gastric cancer related to CagA positive 
H. pylori infection (Brenner et al., 2002). H. pylori infection does not seem to 
associate with adenocarcinoma of the gastric cardia (Wu et al., 2003; Huang et al., 
2003; Ye et al., 2004). A great deal of the decrease in the incidence of gastric cancer 
can be contributed to better hygienic conditions, improved cold storage of food and 
antibiotics with activity against H. pylori. Eradication of H. pylori seems to reduce the 
incidence of gastric cancer, at least among people without precancerous lesions during 
the eradication (Hamajima et al., 2004; Wong et al., 2004; Kaminishi, 2005). Duodenal 
ulcer is strongly associated with H. pylori infection and associates with a reduced risk 
of intestinal metaplasia, which is considered to be a premalignant lesion in the stomach 
(Leung et al., 2004). 
5.3.2 Hereditary and genetic factors 
Families with several first-degree relatives with gastric cancer have a higher risk of 
gastric cancer. There may be a familiar predisposition if two first-degree relatives, one 
younger than 50 years, or at least 3 first-degree relatives irrespective of age have had 
gastric cancer. A relative risk of 2.6 has been reported between the risk of gastric 
cancer and a family history of gastric cancer (La Vecchia et al., 1992). Families with 
frequent gastric cancer at a young age usually develop the diffuse type of gastric 
cancer (Guilford et al., 1998; Gayther et al., 1998; Berx et al., 1998).
Individual immunological, genetic, and immunogenetic factors are important in the 
pathogenesis of gastric cancer. A genetic profile favouring a proinflammatory response 
increases the risk of gastric carcinoma (Shang & Pena, 2005; Zagari et al., 2004). For 
unknown reasons, blood group A may also be associated with an increased risk of 
gastric cancer (Hallstone & Perez, 1994). The risk of gastric cancer among H. pylori
infected persons may also be associated with specific HLA genotypes and 
proinflammatory IL-1 polymorphisms (Magnusson et al., 2001; Rad et al., 2004; Li et 
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al., 2005). A family history of gastric cancer and CagA positive H. pylori infection has 
been related to a more than 8-fold risk of gastric carcinoma and a 16-fold risk of 
noncardia gastric carcinoma, when compared with uninfected subjects with no family 
history (Brenner et al., 2000). However, genetic mechanisms do not seem to play as 
important a role in gastric cancer as for colorectal cancer, and familial clustering of the 
disease might reflect rather environmental factors shared by family members than true 
genetic differences (Goldgar et al., 1994). Interestingly, persons with inherited genetic 
disorders, such as hereditary nonpolyposis colorectal cancer and the inherited breast 
cancer genes BRCA1 and BRCA2, may also be at a higher risk of developing gastric 
cancer (Ericson et al., 2004; Lorenzo Bermejo et al., 2004).
5.3.3 Dietary and lifestyle factors 
In a study on 38,576 atomic-bomb survivors in Hiroshima and Nagasaki there were 
1,270 gastric carcinomas during the follow-up between 1980 and 1999 (Sauvaget et al., 
2005). Exposure to ionizing radiation, male gender, age, and smoking were 
significantly associated with an increased risk of gastric cancer but no association with 
the consumption of fruit, vegetables, green tea, and soy products was observed 
(Sauvaget et al., 2005). Food rich in salt, salted meat, starch, and pickled food seem to 
be risk factors for gastric cancer, while diets rich in fruits and vegetables and low in 
salt and starch tend to have a protective effect (Sauvaget et al., 2003; De Stefani et al., 
2004; Tsugane, 2005; Turkdogan et al., 2005). Smoking and overweight have been 
associated with an increased risk of gastric cardia cancer (Chow et al., 1998; You et 
al., 2000; Wu et al., 2001; Engel et al., 2003; Lindblad et al., 2005), and alcohol 
consumption with an overall risk of gastric cancer (Ji et al., 1996), but this has not 
been the case in all studies (Gammon et al., 1997; Wu et al., 2001; Engel et al., 2003; 
Barstad et al., 2005; Lindblad et al., 2005).
Hyperglycaemia is a risk factor for gastric cancer, especially among H. pylori positive 
subjects (Yamagata et al., 2005). Chilli peppers contain capsaicin and a high intake 
may also associate with an increased risk of gastric cancer (Lopez-Carrillo et al., 
2003). On the other hand, protective effects have been reported from the intake of 
carotenes, lycopene, and vitamin C (Yuan et al., 2004), although controversial results 
are also reported (Lopez-Carrillo et al., 2004). Low levels of dietary vitamin C and H.
pylori infection are associated with an increased risk of gastric cancer (You et al., 
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2000). High levels of vitamin C inhibit the growth of H. pylori in vitro and in vivo 
(Zhang et al., 1997). Nitrite consumption may not (Lopez-Carrillo et al., 2004) or may 
(Engel et al., 2003; Bonney et al., 1987) be associated with the development of gastric 
cancer.
A low socioeconomic status has been linked to an increased risk of gastric cancer 
(Gammon et al., 1997; Tran et al., 2005), especially if associated with a low 
educational status, consumption of smoked, salted, fatty foods, and well water, 
cigarette smoking, poor intake of fresh fruits and vegetables, and poor hygiene (Fujino 
et al., 2002; Turkdogan et al., 2005). 
5.3.4 Gastric stump after previous surgery for benign disease 
Gastric stump cancer is a carcinoma that has developed in the gastric stump after 
partial gastrectomy for some benign gastric disease (Matsui et al., 2001). This 
condition may increase the risk of subsequent gastric cancer (Hansson et al., 2000), but 
this report has been challenged (Luukkonen et al., 1990). However, enteric bile reflux 
and H. pylori may act in synergy on cell proliferation in the stump (Leivonen et al., 
1997). There is evidence that H. pylori is less strongly associated with cancer in the 
stump than otherwise and that intestinal reflux and subsequent reactive gastropathy are 
more important reasons for carcinogenesis in the gastric stump (MacDonald et al., 
2001; Johannesson et al., 2003).
5.3.5 Pernicious anaemia 
Pernicious anaemia and achlorhydria follow type A gastritis affecting the body and 
fundus of the stomach (Toh et al., 1997). Pernicious anaemia is considered to be a risk 
factor for non-cardia gastric cancer (Ye et al., 2003; Brinton et al., 1989; Hsing et al., 
1993; Karlson et al., 2000; Mellemkjaer et al., 1996).
5.3.6 Polyps 
Gastric polyps are proliferative or neoplastic lesions of the gastric mucosal layer, 
protruding into the lumen, and they occur in 2 – 3 % of all gastroscopies (Lau et al., 
1998; Oberhuber & Stolte, 2000). Gastric polyps may be sporadic (Daibo et al., 1987; 
Oberhuber & Stolte, 2000; Park et al., 2001) or associated with polyposis syndromes, 
e.g., familial adenomatous polyposis coli, the Peutz-Jeghers syndrome, juvenile 
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polyposis, and Cowden's disease (Spigelman et al., 1989; Hofgartner et al., 1999; 
Oberhuber & Stolte, 2000). Depending on the type of polyps there is an increased risk 
(2 – 15 %) of gastric cancer (Daibo et al., 1987; Abraham et al., 2002). 
5.3.7 Epstein-Barr virus 
The Epstein-Barr virus cause mononucleosis and has been associated with some 
malignancies as Burkitt’s lymphoma (zur Hausen et al., 1970), nasopharyngeal 
carcinoma (zur Hausen et al., 1970), and gastric cancer (Shibata et al., 1992; Neugut et 
al., 1996). Gastric cancers caused by the Epstein-Barr virus tend to be slowly growing 
and not very invasive.
5.3.8 Ménétrier’s disease 
Ménétrier’s disease is a form of gastritis called giant hypertrophic gastropathy. It is 
characterised of large folding of the stomach, low acid production and 
hypoproteinaemia. The increased risk of gastric cancer in Ménétrier’s disease is mainly 
anecdotal, since the disease is a rarity (Fieber & Rickert, 1981; Wood et al., 1983; 
Simson et al., 1987; Johnson et al., 1995). 
5.4 Treatment 
5.4.1 Curative resection 
Curative surgery (R0 resection according to UICC) is defined as complete removal of 
all gastric cancer with a resection margin devoid of malignancy, both macroscopically 
and microscopically (Hermanek & Sobin, 1987). A resection with residual microscopic 
disease is called R1 and a resection with gross residual disease R2. Patients with local 
disease who undergo R0 resection will most likely survive their disease. Several large 
studies on the prognosis of gastric cancer have shown that curative surgical treatment 
as assessed by the surgeon is an important, independent prognostic factor (Kim et al., 
1998; Kim et al., 2001).
Gastrectomy procedures include 1) total gastrectomy, 2) subtotal gastrectomy for 
tumours of the antrum or distal body, and 3) proximal subtotal gastrectomy or 
oesophago-gastrectomy for cancer of the cardia. Total gastrectomy is not considered 
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necessary if UICC R0 resection can be performed and there is no evidence of 
microscopic or macroscopic residual cancer (Brennan et al., 2005). 
5.4.2 Lymph node dissection 
Radical and curative resection requires also total resection of all involved lymph 
nodes. A D0 dissection is defined as gastric resection with incomplete removal even of 
the perigastric (N1) lymph nodes; D1 dissection is lymphadenectomy of the perigastric 
lymph nodes adjacent to the tumour (N1); D2 dissection includes the nodes along the 
stomach and the nodes along the common hepatic artery, left gastric artery, lienal 
artery, and around the celiac axis (N1 and N2); D3 dissection is lymphadenectomy of 
the N1, N2, and N3 lymph nodes along the portal vein, superior mesenteric vein and 
artery, and the retropancreatic nodes; and D4 dissection is a superextended 
lymphadenectomy that includes the nodes mentioned above together with the N4 
lymph nodes, including the para-aortic nodes as far caudally as the inferior mesenteric 
artery, the nodes along the porta hepatis and along the vena cava. Extended (D2) 
lymph node dissection is the current standard of care in Japan and it is considered safe 
when performed by experienced surgeons (Kodama et al., 1981; Sano et al., 2004).
Even for patients with early gastric cancer extended D2 lymphadenectomy should be 
performed if there is a high risk of lymph node metastases with larger tumours or 
lymphatic or blood vessel invasion (Kim et al., 2004; Hyung et al., 2004). Extended 
lymph node (D2) dissection for patients with histologically node-negative gastric 
cancer with advanced T stage is associated with improved survival (Harrison et al., 
1998; Siewert et al., 1998). Extended D2 lymphadenectomy is reported to be beneficial 
when compared to D1 dissection while morbidity and mortality are unaffected 
(Roukos et al., 1998; Lewis et al., 2002; Degiuli et al., 2004), whereas splenectomy 
and pancreatectomy are linked with increased morbidity but no survival benefit 
(Schmid et al., 2000; McCulloch et al., 2004). Previous studies in European centres 
reported, however, that D2 resection was associated with increased operative mortality 
and postoperative complications (Bonenkamp et al., 1995; Cuschieri et al., 1996).
5.4.3 Adjuvant therapy 
A large number of adjuvant chemotherapy trials over the past decades have been 
conducted, but the results have not been encouraging. A study involving 556 patients 
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with resected adenocarcinoma of the stomach or the gastroesophageal junction 
randomly assigned patients to surgery with postoperative chemoradiotherapy or 
surgery alone. The adjuvant treatment consisted of fluorouracil and leucovorin, 
followed by radiotherapy and one month later of two additional cycles of fluorouracil 
and leucovorin. The median overall survival was 27 months in the surgery-only group 
and 36 months in the chemoradiotherapy group (RH = 1.35, 95 % CI = 1.09 – 1.66; p 
= 0.005). There was a significant reduction in the frequency of relapses in the 
chemoradiotherapy group (p < 0.001). Toxic, therapy-associated effects occurred in 41 
% and 3 patients (1 %) died from toxic effects in the chemoradiotherapy group 
(Macdonald et al., 2001).
In another study involving 260 patients with curative resection for stage II to stage 
IVM0 gastric cancer, the patients were randomised to postoperative adjuvant 
chemotherapy with 5-fluorouracil and cisplatin or to surgery alone. The 5- and 7-year 
overall survival rates were 41.9 % and 34.9 % in the control group compared to 46.6 % 
and 44.6 % in the chemotherapy group (p = 0.22). Only 48.8 % of the patients received 
more than 80 % of the planned dose as a result of toxicity. The rate of recurrence was 
reduced by 30 % in the chemotherapy group (p = 0.03) (Bouche et al., 2005).
According to a recent Cochrane review, chemotherapy significantly improves the 
survival of patients with advanced gastric cancer in comparison to best supportive care 
(Wagner et al., 2005). Combination chemotherapy seems to improve survival further 
compared to single-agent 5-fluorouracil, but the effect is modest. The results on 
survival have been best on combination chemotherapy regimens containing 5-
fluorouracil, an anthracycline and cisplatin: half of the patients are alive at 7 months of 
diagnosis compared to 5.9 months for those on monotherapy. However, combination 
therapies are more toxic than monotherapies. Combination chemotherapy with 
epirubicin, cisplatin and continuous infusion of 5-fluorouracil is tolerated best.
5.5 Prognostic factors
5.5.1 TNM classification 
The tumour-node-metastasis (TNM) stage classification of Union Internationale 
Contre le Cancer (UICC) is the most widely recognised system to classify the spread 
of cancers – also gastric cancer – and it predicts patient outcome (Kirkwood et al., 
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1997; Buonadonna et al., 2003). The TNM classification classifies patients into six 
different groups by depth of penetration into the gastric wall of the primary tumour 
(pT), spread of malignant cells to local lymph nodes (pN), and the presence or absence 
of distant metastases (pM) (Hermanek & Sobin, 1987; Sobin & Wittekind, 2002). A 
clinical classification (cTNM or TNM) is used to describe the pretreatment TNM 
status of the patient and a pathological classification (pTNM) to describe the 
postsurgical histopathological status; both are used clinically. The former is used for 
selecting the treatment modality, and the latter for evaluation of the patient’s prognosis 
and the need for adjuvant therapy.
The UICC TNM classification for gastric cancer was renewed in 1997 and the 5th
edition includes the number of metastatic lymph nodes: pN1 indicates metastases in 1 
– 6, pN2 in 7 – 15, and pN3 in more than 15 regional lymph nodes (Sobin & 
Wittekind, 1997). The 5th edition classifies patients with T4N1-N3M0, T1-T3N3M0 or 
any T, any N and M1 tumours to stage IV (Sobin & Wittekind, 1997), compared to the 
4th edition that classified patients with T4N2M0 or any T, any N and M1 tumours to 
stage IV (Hermanek & Sobin, 1987). The new staging is prognostically more accurate 
than the previous classification, which relied on the anatomic sites of metastatic lymph 
nodes (Fujii et al., 1999; Yoo et al., 1999; Katai et al., 2000; Celen et al., 2003). 
Survival among patients that have been classified into the same stage according to the 
new classification is more homogeneous. The depth of invasion and the new nodal 
staging have emerged as more significant prognostic factors than the previous nodal 
staging method (Yoo et al., 1999). The new UICC classification of nodal involvement 
has also been considered superior to the Japanese classification (Ichikura et al., 1999; 
Ichikawa et al., 2003).
Nodal staging according to the 5th edition (Sobin & Wittekind, 1997) classifies patients 
with more than 15 involved regional lymph nodes into a poor prognosis group (de 
Manzoni et al., 1999; Omejc et al., 2001). However, the requirement that at least 15 
lymph nodes need to be examined, also in pT1 patients, has raised some concern (Nio 
et al., 2003) and prognostic accuracy might be improved by using the ratio of 
metastatic lymph nodes (number of metastatic lymph nodes/number of lymph nodes 
removed) (Kim et al., 1998; Kodera et al., 1998; Kunisaki et al., 2005). The current 6th
edition was published in 2002 and includes some amendments concerning gastric 
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cancer, although the actual stage groups have not changed (Sobin & Wittekind, 2002). 
In the 6th edition, the T2 category is subdivided into T2a (tumour invades the 
muscularis propria) and T2b (tumour invades the subserosa). Adenocarcinomas of the 
gastroesophageal junction are also subdivided into “true” cardial or subcardial 
tumours.
Early gastric cancer is defined as gastric adenocarcinoma restricted to the gastric 
mucosa or submucosa, irrespective of regional lymph node involvement (Murakami et 
al., 1971). In a large retrospective review of 1,475 patients treated at the National 
Cancer Center in Tokyo, only 20 (1.4 %) died of recurrent disease (perioperative 
deaths and patients with noncurative operations excluded) (Sano et al., 1993). Five-
year survival rates of over 90 % have consistently been reported for surgically treated 
early gastric cancer patients (Maehara et al., 1992; Folli et al., 1995; Yokota et al., 
2000) and screening of asymptomatic patients has been instituted in Japan, where the 
disease is prevalent. Now early gastric cancer is diagnosed more often in Japan than in 
the Western countries (Everett & Axon, 1997). The prognosis is most favourable for 
patients with tumours confined to the mucosa and no lymph node metastases (Everett 
& Axon, 1997; Yokota et al., 2000). 
Tumour size is not a part of the TNM stage classification for gastric cancer. Tumour 
size is usually a powerful predictor of prognosis by univariate survival analysis, but it 
does not seem to add prognostic information over and above the penetration depth and 
lymph node metastasis when data is analysed multivariately (Adachi et al., 1997; 
Yokota et al., 2002). Nevertheless, for treatment and prognosis the anatomic extent of 
the disease is not the only factor that needs to be considered (Gospodarowicz et al., 
2001).
5.5.2 Tumour location 
Cardia cancer has generally a worse prognosis than cancer of the distal parts of the 
stomach (Ito et al., 2004).
5.5.3 Age and gender 
The incidence of gastric cancer increases with age. The mean age at diagnosis is 60 – 
70 years and about 10 % of all gastric cancers are diagnosed in patients 40 years or 
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younger. In younger patients the diffuse type of carcinoma prevails (Kath et al., 2000; 
Kokkola & Sipponen, 2001). Prognosis does not seem to be affected by age, once 
survival data is adjusted for TNM stage (Blair & Schwarz, 2001; Kokkola & Sipponen, 
2001; Kim et al., 2005a). Gastric cancer is more common among men than women 
(2:1) in elderly patients; this is a worldwide phenomenon which is independent of the 
incidence of gastric cancer (Kim et al., 2005a; Sipponen & Correa, 2002; Wang et al., 
1996; Medina-Franco et al., 2000). This gender difference is not present among 
younger patients (Grabiec & Owen, 1985; Fujimoto et al., 1994; Sipponen & Correa, 
2002; Kim et al., 2005a). The reasons for this age-related shift is not clear but could be 
related to a protective effect of oestrogen among premenopausal women, different 
initiation of H. pylori infection, or differences in chemical exposure during life 
(Ershler & Longo, 1997; Sipponen & Correa, 2002).
5.5.4 Borrmann’s classification 
Borrmann has classified the macroscopic appearance of gastric tumours into four types 
(Borrmann, 1926). Borrmann type I is characterised by protrusive tumours, type II by 
protrusive and ulcerating, type III by ulcero-infiltrative, and type IV by diffuse 
tumours (linitis plastica). Borrmann type IV cancer is associated with an unfavourable 
prognosis (Chen et al., 2002; Zhang et al., 2004).
5.5.5 Laurén’s classification 
Laurén’s classification is the most common histological classification (Laurén, 1965). 
It distinguishes between two different histological types of gastric cancers and these 
types have different epidemiology, pathogenesis, genetic variation, and prognosis 
(Hermanek & Wittekind, 1995). The intestinal (well differentiated) type is 
characterized by large, distinct cells with large, irregular nuclei and the cells form 
glandular tubular-like structures. The diffuse (undifferentiated) type is more 
infiltrative, lacks the characteristic tubular gland-like structures and consists of small 
single cells in a non-organised pattern (Laurén, 1965).
Among younger patients, the incidence of the intestinal type of tumours has decreased 
along with the total incidence of gastric cancer and the diffuse type predominates 
(Laurén & Nevalainen, 1993). The total decline in gastric cancer incidence has been 
attributed to a decline in both intestinal and diffuse type of gastric cancer (Sipponen et 
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al., 1987; Lundegardh et al., 1991). The diffuse type is more common in gastric cancer 
of the cardia (Kim et al., 2005b) and has usually been reported to associate with a 
worse prognosis than the intestinal type (Yu et al., 1995; Hochwald et al., 2000).
5.5.6 Histological grade 
The histological grade of the tumour refers to an evaluation of whether the malignant 
cells of the tumour represent a particularly aggressive form of gastric cancer or not. 
The grade is usually classified into four categories based on cell differentiation, 
number of mitoses per high power microscope field, adherence of the cells to original 
cells, homogeneity of the cellular pattern, and similarity of structures to the original 
organ. In gastric cancer, grade 1 tumours are well differentiated with similar 
characteristics as the original tissue, grade 2 are moderately well differentiated, grade 3 
are poorly differentiated, and grade 4 are undifferentiated tumours, which cannot be 
recognised as having any characteristics of their tissue of origin. However, histological 
grade is subjective and cannot be determined quantitatively.
5.5.7 Tumour markers 
A tumour marker is a substance whose concentration changes with malignancy in body 
fluids like blood, serum, urine, or peritoneal fluid, or in tissues of patients with cancer. 
A tumour marker may be produced by the tumour itself or by the body in response to 
the tumour. These markers can be used in diagnosis when a malignant tumour is 
suspected, although tumour markers are generally inadequate as screening tests. The 
diagnostic usefulness of tumour markers is determined by their sensitivity and 
specificity. Tumour markers are not unproblematic, since slightly altered 
concentrations are often found in benign conditions. Tumour markers may be useful 
for monitoring the effect or success of treatment and monitoring the course of disease 
once a particular tumour that affects the marker level has been diagnosed. The tumour 
marker concentration may also reflect the spread or the stage of the disease, be a sign 
of how cancer progress and may help determine the prognosis.
Advances in molecular biology have led to discoveries of new molecular markers of 
cancer tumourigenesis, angiogenesis, growth, invasion, and metastasis. An enormous 
effort is being put into studies on the use of oncogenes, tumour-suppressor genes, 
growth factors, growth factor receptors, adhesion molecules, and angiogenic factors as 
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new diagnostic biological markers, therapeutic targets, and prognostic factors of cancer 
(Houshmand & Zlotnic, 2003). Different techniques for identifying molecular changes 
in tumour tissue are available, e.g., polymerase chain reaction (PCR), DNA 
sequencing, immunoblotting, and immunohistochemistry. Immunohistochemistry is 
simple, fast, consistent with other methodologies, and can be applied to several, 
relatively small specimens at the same time, and is therefore a popular method for 
studying tumour markers. The actively dividing cancer cells also express large and 
chromatin-rich nuclei as a sign of an aberrant amount of chromosomes, which can be 
assessed by DNA flow cytometry.
 Syndecan-1 
Syndecan-1 (CD138; gene name SDC1; gene location 2p24.1) is a transmembrane 
heparan sulphate proteoglycan, one of a family of four, named syndecan 1 to 4 based 
on the order of cloning of their cDNAs (Bernfield et al., 1992). Syndecan-1 consists of 
a core protein with a transmembrane domain, a C-terminal cytoplasmic domain and an 
N-terminal extracellular domain, which attaches covalently long, unbranched 
carbohydrate polymers called glycosaminoglycans (GAGs) (Bernfield et al., 1992).
The variable chondroitin sulphate and heparan sulphate chains of the extracellular 
domain of syndecan-1 binds to different extracellular matrix components, such as 
collagen types I, III and V, fibronectin, thrombospondin, tenascin, amphoterin, and 
laminin (Koda et al., 1985; Bernfield & Sanderson, 1990; Salmivirta et al., 1991, 
Salmivirta et al., 1994). The extracellular domain of syndecan-1 stimulates actin 
polymerisation, participates in cell proliferation, suppresses malignant growth in 
different carcinoma cell lines, and regulates complex cell behaviour patterns, e.g., 
motility and invasiveness (Ridley et al., 1993; Liebersbach & Sanderson, 1994; Mali et 
al., 1994; Liu et al., 1998). Syndecan-1 may participate in signal transduction as a 
growth factor receptor, e.g., of the basic fibroblast growth factor (bFGF) (Elenius et 
al., 1990; Bernfield et al., 1992; Rapraeger, 1993). Syndecan-1 contacts the 
cytoskeleton through the cytoplasmic domain, and this mediates its organisation and 
influences cell shape (Elenius et al., 1990).
Syndecan-1 is expressed on all human cells in a way that is specific for cells, tissues 
and developmental stage (Kim et al., 1994; Salmivirta & Jalkanen, 1995). The 
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expression varies by maturation stage and follows morphogenetic rather than 
histological boundaries (Thesleff et al., 1988; Vainio et al., 1989). In adult tissues, 
syndecan-1 is predominantly expressed in the epithelium and this is most prominent in 
stratified squamous epithelia, e.g., the epidermis, the oral mucosa and the vaginal 
mucosa, and in keratinocytes (Hayashi et al., 1987; Inki et al., 1991). Syndecan-1 
contributes to some regenerative processes, e.g., wound healing (Elenius et al., 1991; 
Elenius et al., 2004). Syndecan-1 is present at the basolateral surface of foveolar cells 
of the gastric mucosa, early in the scar tissue at the margins of healing gastric ulcers, 
and in the cells of intestinal metaplasia (Tanabe et al., 1999). 
In mouse keratinocyte cell lines of different morphology and tumourigenicity the 
expression of syndecan was reduced in carcinoma cells compared to their normal 
counterparts (Inki et al., 1992). Loss of syndecan-1 is a characteristic feature of human 
hepatocellular carcinoma that has a high metastatic potential (Matsumoto et al., 1997). 
Loss of immunohistochemical expression of epithelial syndecan-1 correlates with a 
poor prognosis in patients with squamous cell carcinoma of the head and neck (Inki et 
al., 1994; Pulkkinen et al., 1997; Anttonen et al., 1999) and mesotheliomas (Kumar-
Singh et al., 1998). Non-small-cell lung carcinomas, particularly poorly differentiated 
tumours with an invasive phenotype, express syndecan-1 poorly (Nackaerts et al., 
1997), but the stroma of infiltrating ductal breast carcinomas have a strong expression 
(Stanley et al., 1999). Stromal syndecan-1 positivity could be a sign of aggressive 
malignant behaviour in breast tissue, since altered syndecan-1 expression, induction 
within the stroma and reduction or loss of expression the malignant cells themselves, 
could be critical for promoting the metastatic phenotype of infiltrating ductal 
mammary carcinoma. 
 p27 
The 27-kDa-protein p27 (cyclin-dependent kinase inhibitor 1B; CDKN1B; KIP1; gene 
location 12p13.1) is a mitotic inhibitor of the cell cycle. It inhibits cyclin dependent 
kinase activity and interacts strongly with D-type cyclins in complex with cdk4 and – 
to a weaker extent – with cyclin E and cdk2 complexes (Toyoshima & Hunter, 1994). 
It functions as a negative regulator of G1 progression and could be a mediator of TGFβ
induced G1 arrest (Toyoshima & Hunter, 1994). p27 could thus be a tumour 
suppressor – a notion that is supported by reports according to which cells lacking p27 
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expression do not enter a quiescent state (Toyoshima & Hunter, 1994). 
Phosphorylation and degradation via the ubiquitin-proteosome pathway are the main 
regulators of the expression of p27 (Pagano et al., 1995). Changed protein stability 
might be more important for the regulation of p27 levels than changed synthesis of the 
protein (Pagano et al., 1995). At any event, mutations are a rare cause for decreased 
p27 expression in cancer cell nuclei (Ponce-Castaneda et al., 1995). 
Immunohistochemistry seems therefore to be a suitable method for assessing the 
expression of p27 in neoplasias. 
In healthy epithelial tissue the p27 protein is present in a large number of cells. The 
expression is clearly downregulated as a consequence of neoplastic transformation 
(Fernandez et al., 1999; Slingerland & Pagano, 2000; Zucchi et al., 2002). The 
expression of p27 in tumour cells of lymph node metastases is reduced in comparison 
with the primary gastric carcinoma (Kim et al., 2000). In gastric cancer, decreased 
expression of p27 correlates positively with tumour size, grade, lymphatic invasion, 
stage, invasion depth, number of lymph node metastases, and recurrence (Kim et al., 
2000). Loss of p27 expression may be associated with a poor prognosis in patients 
with a variety of solid tumours, including breast (Leivonen et al., 2001), colon (Tenjo 
et al., 2000) and oesophagus cancer (Shamma et al., 2000). The results regarding 
gastric cancer are contradictory. Low expression of p27 has been reported to be an 
independent prognostic factor in several studies (Kwon et al., 1999; Ohtani et al., 
1999; Sgambato et al., 2000), but not all (Feakins et al., 2000; Muller et al., 2000). 
 Tenascin-C 
Tenascin-C (TNC; gene location 9q33) is a large glycoprotein of the extracellular 
matrix with a unique six-armed multidomain macromolecular structure (Schenk & 
Chiquet-Ehrismann, 1994). Other members of the non-collagenous extracellular matrix 
proteins are the laminins (Brown & Timpl, 1995) and fibronectins (Hynes, 1986). 
Extracellular matrix molecules are important for cell proliferation and morphogenesis 
– they guide migration, growth as well as differentiation of cells (Adams & Watt, 
1993).
Tenascin-C is expressed in epithelial-mesenchymal interactions during a period of fetal 
morphogenesis (Aufderheide et al., 1987; Aufderheide & Ekblom, 1988; Erickson & 
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Bourdon, 1989; Natali et al., 1991) and again in adult tissues during wound repair 
(Mackie et al., 1988) and tumourigenesis (Erickson & Bourdon, 1989; Howeedy et al., 
1990; Natali et al., 1991). Tenascin-C is expressed in the muscularis mucosae, 
muscularis propria and vessel walls of healthy gastric tissue, but not in healthy gastric 
mucosa or submucosal connective tissue (Ikeda et al., 1995). 
The expression of tenascin-C seems to increase during tumourigenesis (Pilch et al., 
1999). Cancer cells and adjacent stromal cells may produce tenascin, which seems to 
facilitate co-ordinated growth of the microenvironment surrounding tumours 
(Sakakura & Kusakabe, 1994; Ishihara et al., 1995). Local tumour invasion seems to 
be inhibited by stromal tenascin-C expression (Sugawara et al., 1991) and by covering 
the cancer nest tenascin-C might block cancer invasion. This implies that stromal 
tenascin-C expression could be associated with an improved prognosis (Sakakura & 
Kusakabe, 1994; Ishihara et al., 1995). In gastric cancer, tenascin is present in the 
fibrous stroma surrounding foci of cancer (Mackie et al., 1988; Ikeda et al, 1995). 
Stromal tenascin-C expression has been associated with a better prognosis in cervical, 
colonic and breast cancer (Pilch et al., 1999; Sugawara et al., 1991; Shoji et al., 1993; 
Iskaros et al., 1997). In earlier studies of gastric cancer, stromal tenascin expression in 
the primary tumour has not been shown to correlate with prognosis (Ikeda et al., 1995; 
Ilunga & Iriyama, 1995; Zirbes et al., 1999). 
 TATI 
The 6 kD tumour-associated trypsin inhibitor, TATI, (serine peptidase inhibitor, Kazal 
type 1; SPINK1; gene location 5q32) was first identified in the urine of a woman with 
ovarian cancer (Stenman et al., 1982). It was later found to be identical to the 
pancreatic secretory trypsin inhibitor PSTI (Huhtala et al., 1982). TATI is a strong 
inhibitor of trypsin, by which it is gradually degraded, and inhibits only slightly other 
serine proteinases (Fritz et al., 1967; Huhtala et al., 1982; Turpeinen et al., 1988). In 
the stomach its role is probably to prevent digestion of the gastric mucus (Freeman et 
al., 1990; Playford et al., 1991). In vitro, PSTI/TATI increases cell migration in wound 
repair and it may play a role in repairing tissue after tissue destruction (Marchbank et 
al., 1998). TATI might have an important function for maintaining and repairing tissue 
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and for protecting the mucous membrane against degradation. This raises the thought 
that TATI could also contribute to the inhibition of tumour spread. 
Normally, TATI is expressed in the human pancreas, urinary tract, gall bladder, breast, 
kidney, fetal lung, and mucus-producing cells of the gastrointestinal tract, especially in 
the foveolar cells of the stomach (Fukayama et al., 1986; Haglund et al., 1986; Bohe et 
al., 1987; Freeman et al., 1990; Playford et al., 1994; Marchbank et al., 1996). TATI is 
also secreted into the gastric juice where it is stable under the neutral conditions of the 
protecting mucus layer (Freeman et al., 1990).
In cancers, TATI is often co-expressed with tumour-associated trypsin (Solakidi et al., 
2003), suggesting that TATI plays the same role of protecting against tissue 
destruction in cancers as it does in the pancreas (Stenman, 1990; Stenman et al., 1991). 
TATI is expressed in several forms of cancer tissue, and increased levels of TATI in 
the serum have been reported in pancreatic, colorectal, gastric, lung, ovarian, renal 
cell, and bladder cancers (Haglund et al., 1986; Ogawa et al., 1987; Halila et al., 1988; 
Higashiyama et al., 1990; Loizate Toricaguena et al., 1991; Piantino & Arosaio, 1991; 
Järvisalo et al., 1993; Pasanen et al., 1995; Lukkonen et al., 1999; Paju et al., 2001; 
Kelloniemi et al., 2003). Of patients with gastric cancer 19 – 85 % have increased 
levels of TATI; the concentrations are related to TNM stage (Loizate Toricaguena et 
al., 1991; Piantino & Arosaio, 1991). For patients with ovarian, bladder and renal cell 
cancers, an increased serum level of TATI marks a poor prognosis (Venesmaa et al., 
1994; Venesmaa et al., 1998; Paju et al., 2001; Kelloniemi et al., 2003). TATI/PSTI is 
expressed immunohistochemically in 83 % of gastric adenocarcinomas, but its 
prognostic value has not been previously assessed (Higashiyama et al., 1990). 
 p53 
p53 is a 53-kD nuclear protein also known as tumour protein 53 (TP53; gene location 
17p13.1). It consists of four domains: one that activates transcription factors, a core 
domain that recognises specific DNA sequences, a domain that is responsible for the 
tetramerisation of the protein, and a domain that recognises damaged DNA. p53 is a 
transcription factor that regulates the cell cycle, especially transition from G0 to G1 
(Levine, 1997).
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In non-neoplastic cells, p53 is continually produced and degraded and expression is 
low. The major regulator of p53 is Mdm2 (Moll & Petrenko, 2003). Expression of 
Mdm2 is, in turn, activated by p53 in an autoregulatory feedback loop. Binding of p53 
by Mdm2 can trigger the degradation of p53 via the ubiquitin system and Mdm2 
normally maintains p53 at a low level. DNA damage and other stress signals may 
activate protein kinases to phosphorylate p53, thereby increasing the p53 level and 
disrupt its binding with Mdm2 (Harris & Levine, 2005). Since Mdm2 expression is 
activated by p53, the increase of p53 increases concomitantly with Mdm2, which, 
however, has no biological effect as long as p53 is phosphorylated. After the DNA 
damage is repaired, p53 is quickly dephosphorylated and destroyed by the accumulated 
Mdm2. An increase of p53 proteins induces cell cycle arrest and this prevents 
replication of the damaged DNA and provides the cell with time for enzymatic repair 
of the DNA lesions by proteins, the transcription of which is activated by p53 
(Kuerbitz et al., 1992). As a last resort, p53 can induce cell apoptosis (Yonish-Rouach 
et al., 1991).
If the p53 gene is damaged by mutagens (chemicals, radiation, or viruses), tumour 
suppression is severely reduced and this raises the probability that the cell will begin to 
divide unrestrictedly. Probably the most frequent tumourigenic mutations are those of 
the p53 tumour suppressor gene; more than 50 percent of all human tumours contain a 
mutation or deletion of the p53 gene (Hollstein et al., 1991). These mutations lead 
usually to loss of function of the p53 protein with failure to bind the consensus DNA 
binding site. The consequence of this is that DNA repair becomes defective, genetic 
disorders accumulate, cell ploidy becomes pathological and malignant transformation 
ensues (Kastan et al., 1991; Levine, 1997). People who inherit only one functional 
copy of p53 will most likely develop tumours in early adulthood, a disease known as 
the Li-Fraumeni syndrome. Immunohistochemically detected p53 is frequently (85 %) 
the mutant form, which is more stable than the wild-type p53 (Finlay et al., 1988) and 
does not generally induce Mdm2; this is why the p53 can accumulate at very high 
concentrations in the cell nucleus (Bodmer et al., 1992; Baas et al., 1994). The mutant 
form of the p53 protein can also inhibit normal p53 itself (Blagosklonny, 2002). 
Mutated p53 occurs in several forms of cancer (Hollstein et al., 1991). In gastric 
cancer, immunohistochemical p53 expression has been reported in 13 – 64 % of 
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specimens (Seruca et al., 1992; Zafirellis et al., 2005). Overexpression of p53 may be 
related to a worse prognosis than normal expression in gastric cancer (Martin et al., 
1992; Victorzon et al., 1996a; Lee et al., 2003; Fondevila et al., 2004) but this has not 
been a consistent finding (Motojima et al., 1994; Zafirellis et al., 2005).
 p21 
p21, also called cyclin-dependent kinase inhibitor 1A (CDKN1A, Cip1, Waf1; gene 
location 6p21.2) is a transcriptional target of p53 by which it is activated (el-Deiry et 
al., 1993). However, there are also p53 independent pathways of p21 induction 
(Elbendary et al., 1994). p21 inhibits the phosphorylation of cyclin-cdk2 or cyclin-
cdk4 complexes and induces cell cycle arrest at the G1/S checkpoint (Sheikh et al., 
1995). Evidence is increasing that p21 is also a major inhibitor of p53-induced as well 
as p53-independent apoptosis, but why this is the case is unknown (Cayrol et al., 1998; 
Gartel & Tyner, 2002).
p21 protein is produced in normal gastric mucosa and is lost in gastric cancer (Xie et 
al., 2004). There are no known mutations of the p21 gene (Park et al., 1998). The role 
of p21 for survival prediction is still unclear (Tsihlias et al., 1999). In gastric cancer, 
patients that lack p21 expression in the tumour may have a favourable prognosis 
(Okuyama et al., 2002) but, again, this has not been the case in all studies (Al-
Moundhri et al., 2005). 
 bcl-2 
The bcl-2 protein, coded by the bcl-2 proto-oncogene (gene location 18q21.33), is a 
mitochondrial protein integrated in the outer mitochondrial membrane. bcl-2 is closely 
linked to p53 for apoptosis regulation by inhibiting p53 induced apoptosis (Yonish-
Rouach et al., 1991; Bissonnette et al., 1992; Korsmeyer et al., 1992; Oren et al., 
1992).
Overexpression of bcl-2 is an early event in gastric tumourigenesis. It takes place 
before gastric dysplastic changes are seen (Anagnostopoulos et al., 2005). 
Overexpression of bcl-2 is also linked to suppression of cellular proliferation and to 
less aggressive forms of tumours (Saegusa et al., 1995). The prognostic significance of 
bcl-2 in gastric cancer is still contradictory, as some studies report a favourable 
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prognosis in patients with bcl-2 positive tumours (Inada et al., 1998) and others do not 
(Muller et al., 1998).
5.5.8 DNA ploidy and S-phase fraction (SPF) 
Healthy human cells have 23 pairs of chromosomes, i.e., a total of 46, and are called 
diploid. A disturbed number of chromosomes or chromosome sets is called 
aneuploidy. Aneuploidy is a good marker of a malignant cell population and an 
abnormal amount of DNA in solid tumours is a specific sign of neoplasia (Barlogie et 
al., 1980; Barlogie et al., 1983). DNA flow cytometry measures the DNA amount of 
single cells as they flow past a laser light source that emits coherent light at a specific 
wavelength. The DNA, which has been stained with a fluorescent dye, is exited by the 
laser beam and emits light at a longer wavelength. The emitted light is picked up by 
detectors and the signal is digitally analysed. The technique to analyse the DNA 
amount from single cells in paraffin embedded tumour tissues was describe by Hedley 
et al. (Hedley et al., 1983).
Several studies have reported that aneuploidy is a sign of a poor prognosis in gastric 
cancer (Setälä et al., 1997; Lanza et al., 1998; Pinto et al., 1999; Danesi et al., 2000; 
Russo et al., 2001; Michels et al., 2004). The S-phase fraction (SPF) is a measure of 
the percentage of cells in the DNA synthesis phase of the cell cycle. The S-phase 
fraction can be used together with the proliferative DNA index to give a more 
complete understanding of how aggressively a tumour might be growing. A high SPF 
is apparently a sign of poor prognosis of gastric cancer patients (Ohyama et al., 1990; 
Setälä et al., 1998; Russo et al., 2001). 
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6. AIMS OF THE STUDY
The prognostic evaluation of gastric cancer patients is usually based on the TNM-stage 
classification by the UICC. There is a need for more accurate prognostication as 
treatments develop. Strong prognostic factors facilitate an individualised evaluation of 
prognosis and make it easier to compare treatment results between centres.
The specific aims of this study were to assess:
1. the immunohistochemical expression and prognostic significance of the 
proteoglycan syndecan-1 in tumours from patients with primary gastric cancer 
and its association with known prognostic factors 
2. the immunohistochemical expression of the cell-cycle protein p27 in gastric 
cancer tissue and its association with prognosis and other clinicopathological 
factors
3. the stromal staining pattern of the extracellular matrix protein tenascin-C and to 
evaluate its prognostic significance and association with other prognostic 
variables of patients with gastric cancer 
4. the immunohistochemical expression of the enzyme inhibitor TATI in gastric 
cancer tissue and to assess the association of TATI with patient survival and 
other prognostic factors 
5. the prognostic value of the known markers for apoptosis, p53, p21 and bcl-2, 
and of DNA ploidy and SPF in patients with gastric cancer. SPF and DNA 
ploidy were measured by flow cytometry.
6. all factors studied by multivariate survival analysis to identify novel 
independent prognostic variables representing different aspects of tumour 
biology in gastric cancer.
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7. PATIENTS, MATERIALS, AND METHODS 
7.1 Patients (I-V)
Clinical data were collected from the medical records of 362 patients with gastric 
cancer treated at the Second Department of Surgery, Helsinki University Central 
Hospital between 1983 and 1999. The data included age at diagnosis, gender, 
Borrmann’s classification, Laurén’s classification, histological grade when available, 
depth of tumour penetration (pT), extent of spread to regional lymph nodes (pN), the 
presence or absence of distant metastases (pM), TNM-stage classification, tumour size, 
tumour location, type of surgery, estimated cure by surgery, and clinical outcome. Of 
the patients, 342 underwent surgery for histologically verified gastric adenocarcinoma. 
Four patients were excluded due to lack of clinical data. Archival tissue specimens 
were available of 337 of the patients. TNM-staging was performed according to the 4th
edition UICC staging procedures (Hermanek & Sobin, 1987). There were 52 (15 %) 
stage IA, 48 (14 %) stage IB, 41 (12 %) stage II, 67 (20 %) stage IIIA, 29 (9 %) stage 
IIIB, and 100 (30 %) stage IV patients. Total or partial gastrectomy with extended 
(D2-D4) lymphadenectomy was performed in 34 patients (10 %), total gastrectomy 
and lymphadenectomy (D1) in 161 (48 %), subtotal gastrectomy and 
lymphadenectomy (D1) in 58 (17 %), and partial gastrectomy and lymphadenectomy 
(D1) in 84 (25 %). Of the patients, 176 (52 %) were operated on with curative intent. 
Of the 84 undergoing partial gastrectomy, 27 (32 %) were operated on with curative 
intent. During surgery, 280 (83 %) of the tumours were classified macroscopically into 
the four types of Borrmann (Borrmann, 1926): polypoid (type I), ulcero-fungating 
(type II), ulcero-infiltrative (type III) and diffuse (type IV). Six of the patients had 
adenocarcinoma in the gastric stump after previous partial gastrectomy for non-
malignant disease. Survival data was obtained from patient records and Statistics 
Finland. The survival data was checked in January 2004. The median follow-up time 
for patients alive at the end of follow-up was 12.5 years (range 4.7 – 20.8). The 
clinicopathological characteristics of the patients are presented in Table 1. 
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Table 1. Clinicopathological characteristics of 337 patients with gastric cancer. 
Clinicopathological variable Patients 
Age
 < 66 years 165
 66 years 172
Gender
 Female  163
  Male 174
Stage
 Stage IA 52
 Stage IB 48
 Stage II 41
 Stage IIIA 67
 Stage IIIB 29
  Stage IV 100
Penetration depth 
 Mucosa (T1) 26
 Submucosa (T1) 33
 Muscularis propria (T2)  48 
 Subserosa (T2) 12
 Serosa (T3) 155
  Adjacent structures (T4) 63 




  Not available 1
Distant metastases 
 M0 244
  M1 93
Tumour location 
 Upper 1/3 69
 Middle 1/3 114
 Lower 1/3 126
 Diffuse 20
 Stump 6
  Not available 2
Laurén’s classification 
 Intestinal 142
  Diffuse 195
Borrmann’s classification  
 Type I 51
 Type II 92
 Type III 80
 Type IV 58
  Not available 55
Tumour size median 
 5 cm 185
 > 5 cm 146
  Not available 6
Resectability
 Intent to cure 176
 Non-curative 143
  Not available 18
Histological grade 
 Grade I 18
 Grade II 39
 Grade III 59
 Grade IV 6
 Not available 215
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7.2 Tissue samples (I-V) 
Tissue samples obtained at surgery were fixed in 4 % buffered formaldehyde for 12 to 
48 h, processed, embedded in paraffin, and stored in the files of the Department of 
Pathology, University of Helsinki. An experienced pathologist reviewed all 
haematoxylin and eosin or Alcian blue periodic acid-Schiff (AB-PAS) stainings, with 
the most representative samples chosen for further analysis. Histological classification 
was assessed according to Laurén’s criteria into either intestinal (n = 142) or diffuse (n 
= 195) type (Laurén, 1965) (Table 1).
7.3 Methods 
7.3.1 Immunohistochemistry (I-V) 
For immunohistochemistry, 4-micrometer thick, freshly cut sections of the paraffin-
embedded samples were fixed on pre-treated Super Frost® Plus (Menzer-Gläser, 
Germany) slides and dried for 12 to 24 h at 37°C. Sections were deparaffinised in 
xylene and rehydrated through graded concentrations of ethanol to distilled water. 
Deparaffinised tissue sections were pre-treated in 0.5 % trypsin (Difco Laboratories, 
Detroit, MI, USA) in PBS solution for 30 min at 37°C for tenascin-C, TATI, p21, and 
bcl-2 or in a 700 W microwave oven for 4 x 5 min in an 0.3 % citrate acid buffer, at 
pH 6.0, cooled for 20 min in room temperature and washed in 1:10 phosphate buffered 
saline (PBS):distilled water solution for syndecan-1, p27, and p53 antigen retrieval. 
The sections were incubated in 0.3 % hydrogen peroxide in methanol for 30 min to 
quench endogenous peroxidase activity and incubated in a blocking solution consisting 
of non-immune horse serum, diluted 1:67 for 15 min to block non-specific binding 
sites. The primary antibodies were applied overnight in PBS containing 0.1 % sodium 
azide (Merck Ltd., Poole, UK) and 0.5 % bovine serum albumin (Sigma Chemical Co., 
St. Louis, MO, USA) at room temperature. The primary antibodies were all 
monoclonal (MAb) and are listed in Table 2. For intensification of the primary antigen 
signals of p21 and bcl-2, sections were treated with biotinyl tyramide and streptavidin 
conjugated to horseradish peroxidase (Catalyzed Signal Amplification, K1500, Dako, 
Glostrup, Denmark) following the manufacturer’s instructions. Bound antibody was 
visualised by the avidin-biotin immunoperoxidase technique (ABC) (Vectastain 
ABComplex, Vector Laboratories, Burlingame, CA, USA) following the 
manufacturer’s instructions. Sections were incubated with biotinylated second-layer 
antibody (1:200; Vector Laboratories Inc., Burlingame, CA, USA) and peroxidase-
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labelled ABC for 30 min each. All dilutions were made in PBS (pH 7.2) and all 
incubations in the ABC method were carried out in humid chambers at room 
temperature. Between each step in the staining procedure, the slides were rinsed in 
three changes of PBS.
Table 2. Details on immunohistochemistry and cut-off values of different tumour markers (I-V).
          
Tumour Antibody Dilution Cut-off for  
marker clone  positivity
SDC1 (I) B-B4, Serotec, Oxford, UK 1:100 > 60 % (epithelial)
 stromal staining 
p27 (II) 57; Transduction Laboratories, Lexington, KY, USA 1:500 >5% 
TNC (III) DB7, Biohit Diagnostics, Helsinki, Finland 1:2000 strong stromal 
TATI (IV) EC8, in-house, Finland (Osman et al., 1993) 0.2 g/ml > 50% 
p53 (V) DO7, Dako, Glostrup, Denmark 1:300 > 20% 
p21 (V) 4D10, Novocastra Laboratories, Ltd., Newcastle upon Tyne, UK 1:20 > 20% 
bcl-2 (V) 124, Dako, Glostrup, Denmark 1:20 > 20% 
Abbreviations: SDC1, syndecan-1; TNC, tenascin-C; TATI, tumour-associated trypsin inhibitor. 
The cut-off levels were selected as follows:
• Loss of epithelial syndecan-1 (  60 % of cancer cells positive) was considered 
as an alteration due to malignancy because syndecan-1 is normally expressed in 
gastric mucosa.
• Stromal syndecan-1 was considered either positive or negative. 
• A tumour was considered p27negative if  5 % of the cancer cell nuclei 
expressed p27. 
• Strong stromal tenascin-C immunoreactivity was considered positive as this 
was the cut-off that resulted in the highest significance according to cancer 
specific survival. 
• For TATI there was a cut-off between high (> 50 %) and lower (  50 %) TATI 
expression between which survival clearly differed. 
• For p53, p21 and bcl-2 expression, a cut-off of 20 % (commonly used in the 
literature) was chosen.
The peroxidase staining was visualised with 3-amino-9-ethylcarbazole (A-5754; Sigma 
Chemical Co., St. Louis, MO, USA), 0.2 mg/ml in 0.05 M acetate buffer, pH 5.0, 
containing 0.03 % perhydrol at room temperature for 15 min. Finally, sections were 
lightly counterstained in Mayer’s haematoxylin, cleared in tap water and mounted in 
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an aqueous mounting medium (Aquamount; BDH, Poole, UK). The procedure is 
schematically presented in Figure 2. 
Figure 2. Overview of immunohistochemical staining procedure. Abbreviations: O/N, 
overnight; R/T, room temperature. 
4 m sections cut and 
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7.3.2 DNA flow cytometry (V) 
For DNA flow cytometry a modification of the method of Hedley et al. (Hedley et al., 
1983) was applied (Victorzon et al., 1996b). Two 50-μm sections were treated with 0.4 
mg/ml proteinase K (Sigma Chemical Co., St. Louis, MO, USA) for 30 min at room 
temperature. After filtration, the nuclei were treated with 100 μg/ml ribonuclease to 
remove double-stranded RNA and stained with 50 μg/ml ethidium bromide (Sigma 
Chemical Co., St. Louis, MO, USA) for at least 1 h. The DNA content was determined 
by flow cytometric analysis (FACScan, Becton Dickinson, Mountain View, Calif., 
USA) using 15 mW excitation at 488 nm, and the total emission between 562 and 607 
nm was recorded. The lowest peak was assigned a DNA index (DI) value of 1.00, and 
DI values of other peaks were based on this reference; no standard DI value was used 
as the staining intensity of fixed nuclei varies between samples. Possible hypodiploid 
peaks were identified as diploid and the normal diploid peak as hyperdiploid. If the DI 
was 1.20 or less, i.e., near diploid aneuploid, the sample was considered diploid. The 
S-phase fraction (SPF) was calculated in 274/314 (87 %) of the tumours using the 
Cellfit program of the FACScan flow cytometer or, if there was an abnormal skewness 
of the G1 peak to the right, manually by a modified rectilinear method; the lower SPF 
was chosen. If the sample contained less than 15 % aneuploid cells, the SPF was not 
calculated. At least 10,000 nuclei from each specimen were analysed. The histograms 
were analysed by a pathologist unaware of the patients’ clinical outcome. 
The number of patients and successful staining or flow cytometric results in each study 
is given in Table 3.
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Table 3. Number of patients and immunohistochemical analysis by study. 
Study I II III IV V 
Marker n Time 1983-1996 1983-1996 1983-1996 1983-1999 1983-1999 
SDC1  296     
p27   316    
TNC    314   
TATI     336  
p53      336 
p21      317 
bcl-2      315 
DNA pl      306 
SPF      278 
Abbreviations: SDC1, syndecan-1; TNC, tenascin-C; TATI, tumour-associated trypsin inhibitor; 
DNA pl, DNA ploidy; SPF, S-phase fraction. 
7.3.3 Statistical analyses (I-V)
The χ² test was used to test for associations between categorical factors (I-V), and 
Spearman’s rank correlation (rs) (V) to test for correlations between continuous 
parameters. Bonferroni’s adjustment of the p-value was performed in article V, where 
several variables were compared. Life tables were calculated according to the Kaplan-
Meier method (I-V). Gastric cancer specific survival was calculated from the date of 
diagnosis to date of death due to gastric cancer. Death of intercurrent causes, patients 
alive at the end of follow-up, and patients lost to follow-up were censored. The 
significance of differences in survival between groups was calculated by the logrank 
test, or logrank test for trend if three or more ordered categories were compared (I-V). 
Multivariate survival analysis was performed by backward stepwise Cox proportional 
hazards regression (I-V). A p-value of 0.05 was adopted as the limit for inclusion of a 
variable. The StatView 5.0 software for Windows (SAS Institute Inc., Cary, NC, USA) 




8.1.1 Gastric cancer specific survival 
Figure 3 shows the gastric cancer specific survival curve of the entire series of 337 
patients with gastric cancer and Figure 4 the survival according to the TNM stage. The 
gastric cancer specific 5-year survival was 35.1 % (CI 95 % = 29.8 - 40.4) and the 
median survival time 2.0 years. During follow-up, 214 (64 %) of the patients died of 
gastric cancer; the last observed death due to gastric cancer was at 7.75 years from 
diagnosis.
Figure 3. Cumulative disease specific survival of 337 patients with gastric cancer. 
Figure 4. Gastric cancer specific survival by TNM stage of 337 patients with gastric cancer. 
Stage IA ( ….. , n = 52), stage IB (
….
, n = 48), stage II ( __ . . __, n = 41), stage IIIA ( __ . __ , n = 
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8.1.2 Survival by clinicopathological variables 
Univariate survival analysis of the clinicopathological variables is shown in Table 4. 
Histological grade was analysed only in the first studies because the number of 
patients in whom grade was assessed was incomplete. Grade was not routinely 
recorded.
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Table 4. Univariate analysis of the relationship between preoperative characteristics 
and survival in 337 patients with gastric cancer.       
Clinicopathological Patients  Cumulative 5-year 95 % CI χ² p-value
variable   survival %     
Age 10.37 0.0013
 < 66 years 165 44 36 - 51   
 66 years 172 26 19 - 33     
Gender    1.42 0.23
 Female 163 38 31 - 46   
  Male 174 32 25 - 39     
TNM stage*    224.83 <0.0001
 Stage IA 52 96  90 - 100   
 Stage IB 48 74 61 - 87   
 Stage II 41 40 24 - 56   
 Stage IIIA 67 15  6 - 24   
 Stage IIIB 29 7 0 - 17   
  Stage IV 100 3 0 - 7     
Penetration depth*   130.26 <0.0001
 Mucosa (T1) 26 96 88 - 100   
 Submucosa (T1) 33 78 64 - 93   
 Muscularis propria (T2) 48 62 48 - 77   
 Subserosa (T2) 12 58 30 - 86   
 Serosa (T3) 155 18 12 - 24   
  Adjacent structures (T4) 63 2 0 - 6     
Lymph node metastases*    178.96 <0.0001
 N0 152 67 59 - 74   
 N1 95 14  7 - 22   
 N2 89 4 0 - 8   
  Not available 1       
Distant metastases  137.48 <0.0001
 M0 244 47 40 - 53   
  M1 93 4 0 - 8     
Tumour location    31.00 <0.0001
 Upper 1/3 69 22 12 - 32   
 Middle 1/3 114 49 40 - 59  
 Lower 1/3 126 37 28 - 46   
 Diffuse  20 0 0   
 Stump 6 0 0   
  Not available 2       
Laurén’s classification  0.01 0.96 
 Intestinal type 142 34 26 - 42   
  Diffuse type 195 36 29 - 43     
Borrmann’s classification    26.06 <0.0001
 Type I 51 30  17 - 43   
 Type II 92 50  39 - 61  
 Type III 80 25 16 - 35   
 Type IV 58 17 7 - 27   
  Not available 56       
Tumour size median  67.17 <0.0001
 5 cm 185 53 46 - 60   
 > 5 cm 146 12 7 - 18   
  Not available 6       
Histological grade*   4.09 0.043
 Grade I 19 27 6 - 49   
 Grade II 42 26 12 - 40   
 Grade III 64 21 11 - 31   
 Grade IV 7 0 0   
  Not available 205       
Resectability    195.64 <0.0001
 Intent to cure 176 61  54 - 69  
 Non-curative 143 3 0 - 6   
  Not available 18       
* ; χ² and corresponding p-values were calculated using the logrank test for trend,
other corresponding p-values were calculated using the logrank test.    
Abbreviation: 95 % CI = 95 % confidence interval    
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8.2 Tumour markers 
8.2.1 Syndecan-1 (I) 
 Epithelial syndecan-1 immunoreactivity 
High epithelial syndecan-1 immunoreactivity (> 60 % positive cancer cells) was seen 
in 99 of 296 (33 %) tumours (Table 5). Corresponding to a loss of syndecan-1 
immunoreactivity, moderate staining (21 – 60 %) was seen in 71 (24 %), weak staining 
(5 – 20 %) in 64 (22 %), and no staining (<5 %) in 62 tumours (21 %).
Loss of syndecan-1 immunoreactivity (  60 % of the cancer cells positive) was 
significantly associated with positive stromal syndecan-1 staining (p = 0.002), a higher 
clinical TNM stage (stage II – IV) (p = 0.001), deep penetration of the primary tumour 
(subserosa or deeper) (p = 0.002), regional lymph node metastases (N1 or N2) (p = 
0.001), a tumour size larger than the median (> 5 cm) (p = 0.003), location of the 
primary tumour in the upper third of the stomach (p = 0.001), and intestinal type of 
tumour according to Laurén’s classification (p = 0.008). There was no significant 
association between syndecan-1 immunoreactivity and age (p = 0.67), gender (p = 
0.30), distant metastases (p = 0.26), grade of differentiation (p = 0.23), or Borrmann’s 
classification (p = 0.24). 
The 5-year cumulative survival of patients with high epithelial syndecan-1 expression 
was 47 % as compared to 26 % for patients with loss of syndecan-1 expression 
(moderate, weak and negative) (p = 0.001; Table 5). The median survival times of the 
patients with high, moderate, weak, and no epithelial syndecan-1 expression were 3.5, 
2.1, 2.1, and 2.0 years, respectively (p = 0.002; logrank for trend). The differences in 
survival of patients with negative, weak or moderate epithelial syndecan-1 expression 
was statistically not significant (p = 0.52).
 Stromal syndecan-1 immunoreactivity 
There was stromal syndecan-1 immunoreactivity in 28 of 296 (9 %) tumours (Table 5). 
Positive syndecan-1 stromal expression correlated with Borrmann’s type I cancer (p = 
0.001), loss of (  60 %) epithelial syndecan-1 expression (p = 0.002), and the intestinal 
type of cancer (p = 0.004). Significant associations were not observed between stromal 
syndecan-1 immunoreactivity and age (p = 0.38), gender (p = 0.13), stage of disease (p
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Table 5. Univariate survival analysis of the series of tumour markers and flow 
 cytometric characteristics (I-V).     
Tumour marker Patients
n (%) 
5-year survival % χ² p-value
Syndecan-1, epithelial  10.53 0.001 
 Low (  60 %) 197 (67) 26 
 High (> 60 %) 99 (33) 47 
Syndecan-1, stromal  5.48 0.019 
 Negative 268 (91) 34 
 Positive  28 (9) 16 
p27 0.32 0.57
 Negative (  5 %) 241 (76) 32 
 Positive (> 5 %) 75 (24) 36 
Tenascin-C, stromal  7.79 0.005 
 Low 192 (61) 26 
 Strong 122 (39) 42   
TATI 7.62 0.006
 Low (  50 %) 183 (54) 28   
 High (> 50 %) 153 (46) 43   
p53 10.30 0.001 
 Low (  20 %) 232 (69) 40   
 High (> 20 %) 104 (31) 24   
p21 7.46 0.006
 Low (  20 %) 274 (86) 33   
 High (> 20 %) 43 (14) 20   
bcl-2 2.50 0.11
 Low (  20 %) 291 (92) 32   
 High (> 20 %) 24 (8) 13   
DNA Ploidy  29.89 < 0.0001 
 Diploid 223 (73) 39   
 Aneuploid 83 (27) 13   
SPF 24.18 < 0.0001
 Low (< 7.6 %) 141 (51) 46   
  High (  7.6 %) 137 (49) 19     
Abbreviations: TATI, tumour-associated trypsin inhibitor; SPF, S-phase fraction; 
95 % CI, 95 % confidence interval.   
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= 0.34), penetration depth (p = 0.27), regional lymph node metastases (p = 0.55), 
distant metastases (p = 0.89), tumour size (p = 0.76), or tumour location (p = 0.16). 
Patients with stromal syndecan-1 immunoreactivity had a significantly more 
unfavourable outcome compared to patients with no stromal staining, with 5-year 
cumulative survival rates of 16 % and 34 %, respectively (p = 0.019; Table 5).
By multivariate survival analysis, stromal syndecan-1 immunoreactivity turned out to 
be an independent prognostic factor, in addition to TNM stage, estimated cure by 
surgery, and tumour size. Epithelial syndecan-1 immunoreactivity, regional nodal, and 
distant metastases, histological type, age, gender, Borrmann’s class, grade, and tumour 
location did not add significant prognostic information. Entering the epithelial 
syndecan-1 score levels as a continuous variable did not affect the results, either. 
8.2.2 p27 (II) 
p27 immunoreactivity was very weak or absent (≤ 5 % of the cancer cell nuclei 
positive) in 241 of 316 (76 %) tumours (Table 5), while 301 (95 %) expressed p27 in 
less than 50 % of cancer cell nuclei. There was no significant association between p27 
and the clinicopathological variables; age (p = 0.65), gender (p = 0.78), stage (p = 
0.24), regional nodal metastases (p = 0.74), distant metastases (p = 0.67), penetration 
depth (p = 0.70), tumour location (p = 0.67), Laurén’s class (p = 0.08), Borrmann’s 
class (p = 0.33), tumour size (p = 0.82), grade of differentiation (p = 0.11), or 
estimated cure by surgery (p = 0.72).
In survival analysis, there was no significant difference between patients with p27 
negative (≤ 5 %) and positive (> 5 %) tumours; the cumulative gastric cancer specific 
5-year survival was 32 % and 36 %, respectively (p = 0.57; Table 5).
By multivariate survival analysis stratified by estimated cure by surgery, stage of 
disease was the only independent prognostic factor (p < 0.001). p27 did not add 
significant prognostic information. 
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8.2.3 Tenascin-C (III) 
Tenascin-C immunoreactivity was present within the tumour stroma in 297 of 314   
(95 %) cases. Strong tenascin-C expression was seen in 122 (39 %) of the tumour 
stromas (Table 5), 121 (39 %) stained moderately positive, 54 (17 %) had occasional 
weak staining, and 17 (5 %) tumours were negative for tenascin-C.
There was a statistically significant correlation between strong tenascin-C expression 
and low stage (p = 0.002), superficial tumour penetration (p = 0.02), tumour location at 
the distal third of the stomach (p = 0.03), and estimated cure by surgery (p = 0.008). 
There was no statistically significant correlation between tenascin-C expression and 
nodal status, distant metastases, age, Laurén’s classification, gender, median tumour 
size, or Borrmann’s classification. 
The cumulative gastric cancer specific 5-year survival of patients with strong tenascin-
C expression in tumour stroma was 42 % (95 % CI = 40 – 44 %), compared to 30 % 
(95 % CI = 28 – 33 %) in those with moderate, 20 % (95 % CI = 17 – 23 %) in those 
with occasional and 14 % (95 %CI = 9 – 18 %) in those with negative tenascin-C 
staining (p = 0.006, logrank for trend) (Figure 5), respectively. Patients with strong 
stromal tenascin-C expression were compared to the combined group of patients with 
moderate, weak, and negative staining. This was found to be the cut-off that resulted in 
the highest significance according to cancer specific survival between tenascin-C 
expression groups (p = 0.005; Table 5; Figure 5).
Tenascin-C did not add significant prognostic information after adjustment for TNM 
stage, when analysed by multivariate survival analysis stratified by estimated cure by 
surgery.
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Figure 5. Gastric cancer specific survival according to strong ( ___  ;n = 122) , moderate (__ __;n
= 121), weak ( - - ; n = 54), and negative ( ….. , n = 17) stromal tenascin-C staining (p = 0.006).
8.2.4 TATI (IV) 
TATI immunoreactivity in cancer cells was high in 153 of 336 (46 %) primary 
tumours (Table 5), moderate in 56 (17 %), weak in 56 (17 %), and absent in 71 (21 %).
There was a significant association between high TATI expression and low stage (p = 
0.007), superficial tumours (p = 0.005), absence of nodal metastases (p = 0.015), 
absence of distant metastases (p = 0.022), estimated cure by surgery (p = 0.012), and 
epithelial syndecan-1 expression (p = 0.036). There was no significant association 
between the expression of TATI and age, gender, tumour location, Laurén’s class, 
Borrmann’s class, tumour size, stromal syndecan-1, tenascin-C, or p27 expression. 
The 5-year survival of patients with high TATI expression in the primary tumour was 
43 %, compared to 31 % for patients with moderate, 18 % for patients with weak, and 
34 % for patients with negative TATI expression (p = 0.015, Figure 6). The 5-year 
survival of patients with high TATI expression (43 %) was significantly longer when 
compared to the combined group of patients with moderate, weak and negative 
expression who had a 5-year survival of 28 % (p = 0.006; Table 5). There was no 
significant difference in survival between patients with moderate, weak or negative 
TATI expression (p = 0.29).
TATI did not add prognostic information after adjustment for TNM stage (p < 0.001) 
and age at the time of diagnosis (p = 0.022), when analysed by multivariate survival 
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Figure 6. Gastric cancer specific survival according to high ( ___ , n = 153), moderate (__ __ , n = 
56), weak (__ . __ , n = 56), and negative (….. , n = 71) TATI immunoreactivity (p = 0.015). 
8.2.5 p53 (V) 
p53 immunoreactivity in cancer cell nuclei was observed in 131 of 336 (39 %) 
tumours, whereas 205 (61 %) tumours were p53 negative. High p53 expression (> 20 
% of the cancer cell nuclei positive) appeared in 104 of 336 (31 %) tumours (Table 5). 
There were significant correlations after Bonferroni’s correction at an -value of 
0.00032 between p53 and SPF (rs = 0.38, p < 0.0001) and between p53 and p21 (rs = 
0.22, p < 0.0001). High p53 expression was associated with aneuploid tumours (p = 
0.0002). The intestinal type of tumours had high p53 expression more often than the 
diffuse type of tumours (p = 0.002).
Patients with high (> 20 %) p53 expression had significantly shorter gastric cancer 
specific survival than patients with weak (  20 %) p53 expression; the median survival 
times were 12.7 and 24.5 months, respectively (p = 0.004) and 5-year survivals 24 % 
and 40 % (p = 0.001; Table 5).
8.2.6 p21 (V) 
High p21 expression (> 20 % positive cancer cell nuclei) was seen in 43 of 317 (14 %) 
tumours. p21 was absent in 231 (73 %) of the tumours (Table 5). There was a 
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The prognosis of patients with a high p21 tumour expression was significantly worse 
compared to low expression: the median survival times were 10.5 and 19.9 months, 
respectively (p = 0.007) and the 5-year survival 20 % and 33 % (p = 0.006; Table 5). 
8.2.7 bcl-2 (V) 
High bcl-2 expression (> 20 % positive cancer cells) was observed in 24 of 315 (8 %) 
tumours while 291 (92 %) were negative for bcl-2 (Table 5). After Bonferroni’s 
correction, high bcl-2 associated with positive p27 expression (p < 0.0001).
There was no significant difference in survival between patients with expression of 
bcl-2 and a lack of expression of bcl-2 (p = 0.11; Table 5). 
8.2.8 DNA ploidy (V) 
The DNA index (DI) could not be estimated in 7 (2 %) of the 313 tumours because of 
background debris or a low number of intact cells. The median coefficient of variation 
(CV) was 6.9 %. Of the 306 tumours, 83 (27 %) were aneuploid and 223 (73 %) 
diploid (Table 5). The 7 near-diploid tumours (DI 1.0 – 1.2) were analysed as diploid. 
Aneuploidy was associated with high TNM stage (p < 0.0001), high p53 expression   
(p = 0.0002), intestinal type of tumours according to Laurén (p < 0.0001), high SPF   
(p < 0.0001), and high epithelial syndecan-1 (>60 %) expression (p = 0.0003). 
The survival time was significantly shorter in patients with aneuploid than diploid 
tumours: the 5-year survivals were 13 % and 39 %, respectively (p < 0.0001; Table 5; 
Figure 7a). This was especially evident in the pT1-2 subgroup, where the 5-year 
survivals were 13 % and 82 %, respectively (p < 0.0001; Figure 7b).
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Figure 7a-b. Gastric cancer specific survival of patients with diploid vs. aneuploid tumours 
including all stage groups (Fig. 7a) and of patients with pT1-2 tumours (Fig. 7b). The difference 
in survival between the groups is significant (p < 0.0001). 
8.2.9 SPF (V) 
The median SPF of all tumours was 7.6 %. SPF could not be assessed in 40 tumours. 
In diploid tumours, the median SPF was 6.7 %, compared to 27.9 % in aneuploid. A 
statistically significant correlation was found between SPF and p53 (rs = 0.38, p < 
0.0001) and tumour size (rs = 0.26, p < 0.0001). A high SPF (  7.6 %) was associated 
with advanced stage (p = 0.0003), moderate to high TATI expression (p = 0.0002), 
intestinal type of tumours (p < 0.0001), non-curative surgery (p < 0.0001), aneuploid 
tumours (p < 0.0001), and loss of epithelial syndecan-1 (p < 0.0001). 
Survival time was significantly shorter of patients with a high SPF than with a low 
SPF: the 5-year survivals were 19 % and 46 %, respectively (p < 0.0001; Table 5; 
Figure 8a). The difference was especially marked in the subgroup of patients with non-
metastatic disease (pM0) with 5-year survival percentages of 30 % and 56 %, 
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Figure 8a-b. Gastric cancer specific survival of patients with high SPF  7.6% vs. low SPF < 
7.6% tumours including all stage groups (Fig. 8a) and of patients with unmetastasized pM0 
tumours (Fig. 8b). The difference in survival between the groups is significant (p < 0.0001). 
8.3 Multivariate survival analysis (V) 
The combined multivariate survival analysis included all prognostic factors available.  
Here, penetration depth (pT) emerged as the most significant independent prognostic 
factor, followed by the presence of regional lymph node metastases (pN), estimated 
cure by surgery, p53 expression, DNA ploidy, p21 expression, and age (Table 6). The 
following variables did not predict independently outcome at the 5 % significance 
level: epithelial or stromal syndecan-1, tenascin-C, TATI, distant metastases, tumour 
size, SPF, gender, tumour location, and Borrmann’s class. Age and tumour size were 
analysed as continuous variables. Tumour location was nominally coded. All the other 
variables were coded into categories as in Table 4 and Table 5. Entering SPF as a 

















0 2,5 5 7,5 10 12,5 15 17,5
Years of follow-up 
SPF  7.6 % pM0 (n = 85)



















0 2,5 5 7,5 10 12,5 15 17,5
Years of follow-up
SPF < 7.6 % (n = 141)
SPF 7.6 % (n =137)
p < 0.0001 
Fig. 8a 
52
Table 6. Stepwise multivariate survival analysis by Cox’s proportional hazards model of 
prognostic covariates of survival in 285 patients with gastric cancer.
          
Covariate p-value RH CI 95 %  coefficient 
pT status <0.0001  
 T1  1.00  
 T2 0.080 2.280 0.905 - 5.746 0.824 
 T3 0.0015 4.113 1.719 - 9.837 1.414 
 T4 <0.0001 7.038 2.867 - 17.276 1.951 
pN status <0.0001  
 N0 1.00   
 N1 0.0004 2.232 1.426 - 3.493 0.803 
 N2 <0.0001 4.259 2.491 - 7.284 1.449 
Resectability 0.0006 2.105 1.374 - 3.225 0.745 
p53 0.004 1.582 1.158 - 2.159 0.458 
DNA ploidy 0.011 1.499 1.098 - 2.047 0.405
p21 0.018 1.671 1.092 - 2.556 0.513 
Age 0.031 1.014 1.001 - 1.027 0.014
RH = relative hazard. CI 95 % = confidence interval at 95 % level.
pT, pN, resectability, p53, DNA ploidy, and p21 were categorically coded (Table 4 and 5). 
Age was analysed as a continuous variable. 
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9. DISCUSSION 
9.1 Epithelial and stromal syndecan-1 expression
In paper I, loss of epithelial syndecan-1 expression and gain of stromal syndecan-1 
expression were associated with an unfavourable disease specific survival (Table 5). 
Similar results have previously been reported for other cancers. Reduced epithelial 
syndecan-1 expression is associated with a decreased disease specific life expectancy 
in squamous cell carcinoma of the head and neck, in laryngeal cancer and in 
mesotheliomas (Anttonen et al., 1999; Pulkkinen et al., 1997; Kumar-Singh et al., 
1998).
A low number (  60 %) of syndecan-1 positive cancer cells in the tumour was 
associated with intestinal type of tumour (according to Laurén), deep penetration, and 
location of the tumour in the upper third of the stomach. Low syndecan-1 expression 
was also associated with large (> 5 cm) primary tumours, positive nodal status (N0 vs. 
N1-2), and advanced clinical stage. These finding are similar to what has been reported 
for head and neck carcinoma (Anttonen et al., 1999).
Syndecan-1 is expressed in the stroma of cancer tissue (Stanley et al., 1999). 
Syndecan-1 is strongly expressed in the stroma of infiltrating ductal breast carcinomas, 
but absent from the stroma of the healthy breast tissue and of stromal-epithelial 
neoplasms. Changes in syndecan-1 expression, induction within the stroma and 
reduction or loss in the malignant cells, could be critical for promoting the metastatic 
phenotype of infiltrating ductal carcinoma of the breast (Stanley et al., 1999). The 
proportion of tumours with a positive stroma was low, only 9 % (Table 5). Stromal 
syndecan-1 expression was associated with the intestinal type of cancer, Borrmann’s 
type I cancer and weak (  60 %) epithelial syndecan-1 expression. Patients with a 
syndecan-1 positive stroma had a significantly reduced survival time compared with 
patients who did not stain for syndecan-1 in the stroma (Table 5).
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The adhesion molecule syndecan-1 can suppress tumour cell invasion and tumour 
growth (Mali et al., 1994). Expression of syndecan-1 in tumour cells might therefore 
be associated with a better prognosis, and this is, in fact, supported by the present 
finding. Loss of syndecan-1 on the surface of cancer cells might be a necessary 
condition for migration of metastatic cells. Stromal expression of syndecan-1 could be 
associated with loss of epithelial expression, decreased cell adhesion and degradation 
of basement membranes. Thus, stromal syndecan-1 positivity may be a sign of 
aggressive malignant behaviour (Stanley et al., 1999). 
9.2 Nuclear p27 expression 
In paper II, there was no difference in survival between patients with low or high p27 
immunoreactivity (Table 5).
Loss of p27 expression was frequent; 95 % of the tumours had p27 expression in < 50 
% of cancer cell nuclei. The corresponding percentages in previous studies have 
ranged from 48 to 82 %, independently of geographical regions (Kwon et al., 1999; 
Ohtani et al., 1999; Feakins et al., 2000; Muller et al., 2000; Sgambato et al., 2000). A 
low expression of p27 is a predictor of a poor prognosis of patients with various solid 
cancers, including breast, colorectal and oesophageal cancers (Shamma et al., 2000; 
Tenjo et al., 2000; Leivonen et al., 2001). However, there are also studies on 
oesophageal cancer that have failed to find a prognostic value for p27, as well (Itami et 
al., 1999). Results in gastric cancer studies are also controversial. Ohtani et al., Kwon 
et al. and Sgambato et al. in their studies on 225, 115 and 96 gastric cancer patients, 
respectively, found that loss of p27 is an independent predictor of poor survival by 
multivariate analyses (Kwon et al., 1999; Ohtani et al., 1999; Sgambato et al., 2000). 
There is also an association between p27 expression and depth of tumour invasion 
(Ohtani et al., 1999), lymph node metastases (Ohtani et al., 1999), poorly differentiated 
histology (Ohtani et al., 1999), diffuse type of tumours (Kwon et al., 1999), and 
lymphatic invasion (Ohtani et al., 1999). In study II there were no significant 
associations between the expression levels of p27 and the common clinicopathological 
variables (age, gender, TNM stage of disease, grade of differentiation, Laurén’s class, 
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Borrmann’s class, depth of cancer invasion, lymph node, distant metastases). This 
observation is in concordance with two earlier studies on gastric cancer. Feakins et al. 
found no evidence of an association between p27 immunoreactivity and gastric cancer 
specific outcome or stage, age, gender, tumour differentiation or histological type in a 
series of 71 gastric cancer patients (Feakins et al., 2000). Muller et al. in their study on 
413 patients who had undergone potentially curative surgery observed no independent 
prognostic value of p27 expression by multivariate survival analysis, nor did they 
register any correlation between p27 expression and the common prognostic 
parameters (depth of invasion, lymph node metastases, blood or lymphatic vessel 
invasion, type, WHO, Laurén’s class) (Muller et al., 2000).
9.3 Stromal tenascin-C expression
Gastric cancer patients with strong tenascin-C immunoreactivity in the tumour stroma 
had a significantly longer cancer specific survival than patients with no or moderate 
tenascin-C expression (Table 5; Figure 5) as shown in paper III. Strong stromal 
tenascin-C expression was more common in tumours of the distal third of the stomach, 
in superficial tumours with penetration from mucosa to subserosa (pT1-2) and in 
tumours of clinical TNM stage I. In a previous report on 203 patients with gastric 
cancer there was a strong correlation between tenascin-C expression and intestinal type 
of cancer (Zirbes et al., 1999), but the present study did not identify such an 
association.
Stromal tenascin-C expression has been associated with a better overall survival of 
patients with cancer, whereas epithelial tenascin-C may be tumour growth promoting 
(Sakakura & Kusakabe, 1994; Ishihara et al., 1995). The present results confirm earlier 
findings in colorectal (Sugawara et al., 1991; Iskaros et al., 1997), breast (Shoji et al., 
1993) and cervical (Pilch et al., 1999) cancer studies, where patients with tenascin-C 
expression in the tumour stroma have had a longer cancer specific survival than 
patients with reduced stromal expression of tenascin-C. Among the present patients, 
the cancer specific survival increased with increasing stromal tumour tenascin-C 
immunoreactivity (Figure 5). However, tenascin-C correlated strongly with TNM stage 
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and therefore did not emerge as a prognostic factor independent of stage in 
multivariate survival analysis. Three previous studies on gastric cancer patients have 
not either shown any prognostic value of tenascin-C (Ikeda et al., 1995; Ilunga & 
Iriyama 1995; Zirbes et al., 1999). In one of these studies the same antibody was used 
as in the present one (DB7), but the antigen retrieval method was different (Ikeda et 
al., 1995). This patient series included only 85 surgically treated gastric cancer patients 
and reported a much lower rate of tenascin-C expression. The immunohistochemical 
methods in the other two studies differed from that of the present one by antibody or 
antigen retrieval (Ilunga & Iriyama 1995; Zirbes et al., 1999). 
Tenascins contain a large number of fibronectin type III repeats which vary in different 
tenascin-C splice variants (Chiquet-Ehrismann et al., 1994). Different splice variants 
may have various functions (Ghert et al., 2001). In cell culture studies, for example, 
purified tenascin-C can promote cellular adhesion or detachment as well as stimulate 
or inhibit cell division, probably due to activities of the different domains of the 
molecule (Erickson, 1993; Faissner et al., 1994). A recent in vitro study has shown 
different adhesive properties between different tenascin-C splice variants (Ghert et al., 
2001). Large differences in the diagnostic value of distinct tenascin-C MAbs have also 
been reported (Dueck et al., 1999). These findings could explain some of the 
contradictory results in gastric cancer prognostic studies. Epithelial tenascin-C might 
support the outgrowth of carcinoma cells, whereas stromal tenascin, by covering the 
cancer nest, might hinder cancer invasion (Sakakura & Kusakabe, 1994; Ishihara et al., 
1995). In paper III, stromal tenascin-C expression was significantly associated with 
penetration depth: expression was less common in tumours penetrating to the serosa 
and adjacent structures. These findings support the hypothesis that tenascin-C may be 
a tumour invasion-limiting factor. If this is the case, this finding may have important 
clinical implications, also suggested previously (Sugawara et al., 1991).
9.4 Tissue expression of tumour-associated trypsin inhibitor (TATI) 
Expression of TATI was present in 79 % of the analysed tumours in paper IV. Patients 
who had a tumour with high immunohistochemical expression of TATI had a 
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significantly longer cancer-specific survival than those with negative, low or moderate 
expression (Table 5; Figure 6). 
TATI, identical to pancreatic secretory trypsin inhibitor PSTI, is a strong inhibitor of 
trypsin (Fritz et al., 1967; Huhtala et al., 1982; Turpeinen et al., 1988). TATI and 
trypsin are co-expressed in neoplasms (Solakidi et al., 2003). TATI is expressed in 
mucus producing cells of the normal gastric mucosa and secreted into the gastric juice 
probably preventing proteolytic digestion of the gastric mucus (Freeman et al., 1990; 
Playford et al., 1991; Marchbank et al., 1998). In atrophic gastritis, stomach ulcers and 
areas of intestinal metaplasia the expression of TATI is decreased, which could be a 
sign of a decreased mucosal defence mechanism that might allow progression of the 
gastric process over time (Bohe et al., 1987; Playford et al., 1994). PSTI/TATI may 
also stimulate repair after mucosal damage (Marchbank et al., 1998). The results of the 
present study support a protective role of TATI against tumour invasion. A high TATI 
expression associated statistically significantly with low TNM stage, superficial 
tumours, lack of nodal and distant metastasis, and high expression of epithelial 
syndecan-1 in paper IV.
However, the associations are contradictory to those between serum levels of TATI 
and indicators of tumour aggressiveness. In gastric cancer, elevated serum levels of 
TATI are associated with advanced disease stage (Loizate Toricaguena et al., 1991; 
Piantino & Arosaio, 1991). An increase in serum levels of TATI is a prognostic marker 
and indicator of an unfavourable prognosis of patients with ovarian, bladder and renal 
cell cancer (Venesmaa et al., 1994; Venesmaa et al., 1998; Paju et al., 2001; 
Kelloniemi et al., 2003). The association between a poor outcome of patients with high 
serum levels of TATI may be explained by degradation of basement membranes in 
aggressive disease with loss of tissue architecture and an increased release of TATI 
into the circulation. This would explain the discrepancy between the current findings 
that high TATI expression in tumour tissue is associated with a better prognosis (Table 
5) and that high levels of TATI in serum associates with a poor prognosis (Loizate 
Toricaguena et al., 1991; Piantino & Arosaio, 1991; Venesmaa et al., 1994; Venesmaa 
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et al., 1998; Paju et al., 2001; Kelloniemi et al., 2003). In a previous report on gastric 
cancer, tissue expression of PSTI/TATI was associated with advanced TNM stage, 
deeper penetrating tumours and nodal involvement in intestinal type of tumours 
(Higashiyama et al., 1990). The overall percentage of positive cancer cells (83 %) was 
similar to that in the present study (79 %). There are certain differences between the 
studies that could explain the discrepant results. The antibody, a polyclonal PSTI 
antiserum, differed from the monoclonal antibody used in the present study, which has 
proven to be highly sensitive for TATI (Osman et al., 1993). In the present study, a 
four-level scoring was used, whereas PSTI expression in the previous study was 
analysed only in terms of positive or negative. The earlier study presented no 
prognostic data. In a study on patients with ovarian cancer, TATI tissue expression 
was associated with adverse cancer specific survival (Paju et al., 2004). However, this 
was found to be the case only in a limited number of patients with stage III and IV 
cancer.
In paper IV, the prognosis was significantly more favourable for patients with high 
TATI expression in the tumour tissue when compared to the groups with negative, low 
or moderate TATI expression, separately or as a group (Table 5). The difference in 
survival was not significant between the groups with moderate, weak, or negative 
TATI expression and hence the TATI cut-off level was set high for purposes of 
statistical analysis (> 50 % of cancer cells positive). Interestingly, the prognosis of 
patients with TATI negative tumours was similar to the prognosis as of patients with 
moderately stained tumours. This suggests a protective role for TATI against tumour 
invasion, possibly by reducing the proteolytic activity of trypsin and thereby by 
inhibiting tissue destruction and mucosal degradation. 
9.5 Combined analysis of previous markers and p53, p21, bcl-2, DNA ploidy, and 
SPF
Although some markers turned out to be prognostically independent of TNM stage or 
the T, N and M factors, it is important to run multivariate survival analyses and to 
combine information from several tumour markers (Gospodarowicz et al., 2001; 
Partridge et al., 2005). In paper V , p53 and p21 expression, and DNA ploidy emerged 
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as independent markers of patient prognosis, in addition to depth of penetration (pT), 
regional nodal status (pN), estimated cure by surgery, and age (Table 6). 
These results are in concordance with several gastric cancer studies that identify p53 as 
a prognostic factor (Martin et al., 1992; Joypaul et al., 1994; Starzynska et al., 1996; 
Victorzon et al., 1996a; Ichiyoshi et al., 1997; Ikeguchi et al., 1998; Setälä et al., 
1998). The other independent prognostic tumour marker was p21, which is activated 
by wild-type p53 and inhibits progression of the cell cycle (Cayrol & Ducommun, 
1998). There is, however, evidence that p21 is also a major inhibitor of apoptosis, 
which may or may not be dependent on p53, but the exact pathophysiological 
mechanisms are unclear (Cayrol et al., 1998; Gartel & Tyner, 2002). Some reports 
claim that p21 is a predictor of an unfavourable outcome (Gomyo et al., 1997; Liu et 
al., 2001; Xiangming et al., 2000; Aoyagi et al., 2003), but others have failed to show 
any prognostic value of p21 to gastric cancer patients (Muller et al., 1999; Kaye et al., 
2000).
DNA ploidy was also an independent predictor of survival here, as has been reported 
previously in a different series of gastric cancer patients (Victorzon et al., 1996b). SPF 
was not an independent prognostic factor by multivariate survival analysis, probably 
because of its strong association with DNA ploidy. The traditional prognostic 
indicators, penetration depth (pT) and regional nodal status (pN), remained the 
strongest predictors of survival. Because the pM-status associated strongly with the 
type of surgery (with or without curative intent), it did not emerge as an independent 
factor. The markers syndecan-1, tenascin-C, and TATI were not significant prognostic 
markers after adjustment for the above-mentioned factors in paper V. Nor did the 
markers bcl-2 and p27 show prognostic value by univariate survival analysis; they 
were not included in the multivariate analysis. 
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10. CONCLUSIONS
In gastric cancer patients: 
1. loss of syndecan-1 in the epithelium in surgically treated patients is associated with 
a poor outcome. Expression of syndecan-1 in the stromal tissue is also associated with 
a poor outcome and seems to be a prognostic factor independent of tumour stage, 
estimated cure by surgery, and tumour size.
2. the expression of p27 protein in the tumour tissue is not associated with outcome. 
There was no correlation between expression of p27 and the conventional 
clinicopathological variables age, gender, stage of disease, depth of cancer invasion, 
lymph node or distant metastases, grade of differentiation, histological type according 
to Laurén, or Borrmann’s class. 
3. strong stromal expression of tenascin-C is associated with a favourable prognosis. 
Tenascin-C expression associates with the depth of tumour invasion and may not add 
significant prognostic information to that provided by TNM stage. 
4. a high expression of TATI in tumour tissue is associated with a favourable 
prognosis, although TATI did not turn out to be an independent predictor of survival 
by multivariate analysis.
5. p53 and p21, but not bcl-2, have independent prognostic value: high expression is 
associated with a worse prognosis. Patients with aneuploid tumours and tumours with 
a high SPF have an unfavourable prognosis.
6. multivariate survival analysis showed that p53 expression, p21 expression, and 
DNA ploidy are independent prognostic variables, in addition to the conventional 
variables pT- and pN-status, estimated cure by surgery, and age. Epithelial and stromal 
syndecan-1, stromal tenascin-C and TATI immunoreactivity did not add significant 
prognostic information in the combined multivariate survival analysis. 
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11. SUMMARY 
The estimated prognosis of patients with gastric cancer is important, not only for the 
patient, but also for the planning of treatment. The most established prognostic factor 
is the UICC TNM-stage classification. However, there is a considerable variation in 
survival of patients within the separate stage groups and there is a need for other 
prognostic markers to improve the accuracy of prognostication.
This study used immunohistochemistry to assess the expression of tumour markers 
involved in different phases of tumourigenesis: markers of cell-cell (syndecan-1) or 
cell-extracellular matrix (tenascin-C) adhesion, cell-cycle regulation (p27, p21, p53), 
proteinase inhibition (TATI), and apoptosis (p53, p21, bcl-2). The DNA ploidy status 
and S-phase fraction (SPF) of the tumours as markers of proliferation were assessed by 
flow cytometry. The final aim was to identify novel prognostic markers in gastric 
cancer and to test them with the classical prognostic factors in a multivariate model to 
improve the accuracy of prognosis assessment for patients with gastric cancer.
Tumour markers that associated with an unfavourable prognosis in univariate survival 
analysis were loss (  60 % of the cancer cells surface stained) of syndecan-1 
expression, stromal syndecan-1 immunoreactivity, low stromal tenascin-C intensity, 
low (  50 % of cancer cells stained) TATI expression, high (> 20 % of cancer cell 
nuclei stained) p53 expression, high (> 20 % of cancer cell nuclei stained) p21 
expression, aneuploidy, and a high (  7.6 %) SPF. Other characteristics associated 
with unfavourable survival in univariate analysis were, in order of significance, high 
TNM stage, non-curative surgery, regional lymph node metastases, deep penetrating 
tumours, presence of distant metastases, large tumour size, tumour location in the 
upper third of the stomach, linitis plastica (Borrmann’s type IV), and advanced age. 
There was no statistically significant difference in survival between patients by gender 
or by Laurén’s classification (intestinal or diffuse type) of tumours. The cell-cycle 
inhibitor p27 and the apoptosis inhibitor bcl-2 did not turn out to have prognostic 
value.
Multivariate survival analysis adjusted for all prognostic variables available showed 
that the most significant variables were penetration depth (pT) and the presence of 
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regional lymph node metastases (pN), followed by curative intent of surgery, p53 
expression, DNA ploidy, p21 expression, and age. As an example, the risk of death 
due to gastric cancer of a patient with a cancer of pT4 (RH 7.038), pN2 (RH 4.259), 
high p53 expression (RH 1.582), aneuploidy (RH 1.499), high p21 expression (RH 
1.671), non-curative surgery (RH 2.105), and one year more age (RH 1.014), is 19.2 
times higher than for a one year younger patient with a pT1, pN0 tumour with weak 
p53 and p21 expression, diploidy, and curative surgery. Although syndecan-1, 
tenascin-C, and TATI were promising prognostic markers by univariate survival 
analysis, they provided no significant prognostic information in the final combined 
multivariate survival analysis.
Continuous advances in molecular biology call for consensus concerning the processes 
and standardisation of immunohistochemical, flow cytometric and other prognostic 
studies to maximise accuracy and reproducibility to the benefit of gastric cancer 
patients. These topics must be periodically revisited and revised. Currently, the 
methods are largely suited for research only, since the study techniques and results of 
different clinical centres vary widely. Although p53, p21 and DNA ploidy emerged as 
independent prognostic factors in this study, there is a need for more and larger studies 
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